: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Inflammatory Bowel Diseases

Free Subscription

Articles published in Aliment Pharmacol Ther
Retrieve available abstracts of 622 articles:
HTML format

Single Articles

September 2024

GRANOT M, Kopylov U, Loberman-Nachum N, Krauthammer A, et al
Differences in disease characteristics and treatment exposures between paediatric and adult-onset inflammatory bowel disease using a registry-based cohort.
Aliment Pharmacol Ther. 2024 Sep 10. doi: 10.1111/apt.18264.
PubMed Abstract available

GRELLIER N, Kirchgesner J, Uzzan M, McLellan P, et al
Early ileal resection in Crohn's disease is not associated with severe long-term outcomes: The ERIC study.
Aliment Pharmacol Ther. 2024 Sep 5. doi: 10.1111/apt.18247.
PubMed Abstract available

PAL P, Mateen MA, Pooja K, Marri UK, et al
Leveraging existing mid-end ultrasound machine for point-of-care intestinal ultrasound in low-resource settings: Prospective, real-world impact on clinical decision-making.
Aliment Pharmacol Ther. 2024;60:633-647.
PubMed Abstract available

FERREIRO-IGLESIAS R, Porto Silva S, Marin S, Casanova MJ, et al
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
Aliment Pharmacol Ther. 2024;60:604-612.
PubMed Abstract available

LING LUNDSTROM M, Peterson C, Hedin CRH, Bergemalm D, et al
Faecal biomarkers for diagnosis and prediction of disease course in treatment-naive patients with IBD.
Aliment Pharmacol Ther. 2024;60:765-777.
PubMed Abstract available

August 2024

JIANG F, Yang W, Cao Y, Cao X, et al
The contribution of dietary advanced glycation end-products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study.
Aliment Pharmacol Ther. 2024 Aug 23. doi: 10.1111/apt.18218.
PubMed Abstract available

ZHAO J, Xue E, Zhou S, Zhang M, et al
Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Aug 21. doi: 10.1111/apt.18217.
PubMed Abstract available

GIBSON PR, Yao CK, Halmos EP
Review article: Evidence-based dietary management of inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Aug 20. doi: 10.1111/apt.18214.
PubMed Abstract available

SOLITANO V, Siegel CA, Korzenik JR, Maratt JK, et al
Performance of bowel preparation quality scales in patients with Crohn's disease.
Aliment Pharmacol Ther. 2024 Aug 11. doi: 10.1111/apt.18210.
PubMed Abstract available

CROFT A, Okano S, Hartel G, Lord A, et al
A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis.
Aliment Pharmacol Ther. 2024 Aug 7. doi: 10.1111/apt.18190.
PubMed Abstract available

MATHIAS RM, Bryant RV
Letter: Light in the lumen-The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Aug 6. doi: 10.1111/apt.18161.
PubMed

MUJAGIC Z, Aliu A, Bosch DHCA, Keszthelyi D, et al
Letter: Light in the lumen-The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease. Authors' reply.
Aliment Pharmacol Ther. 2024 Aug 6. doi: 10.1111/apt.18196.
PubMed

SELINGER CP, Baillie S, Pollok R
Letter: Addressing opioid exposure and associated harms in patients with IBD.
Aliment Pharmacol Ther. 2024;60:423-424.
PubMed

CHATTERJEE A, Yadav AI, Sekar A, Singh H, et al
Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease.
Aliment Pharmacol Ther. 2024;60:537-539.
PubMed

CROUWEL F, Simsek M, de Boer MA, van Asseldonk DP, et al
Multicentre study and systematic review: Allopurinol exposure during pregnancy.
Aliment Pharmacol Ther. 2024;60:503-518.
PubMed Abstract available

July 2024

FEAGAN BG, Matsuoka K, Rogler G, Laharie D, et al
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study.
Aliment Pharmacol Ther. 2024 Jul 31. doi: 10.1111/apt.18158.
PubMed Abstract available

SEQUIER L, Caron B, Loeuille D, Honap S, et al
Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Jul 30. doi: 10.1111/apt.18194.
PubMed Abstract available

LAN Q, Guo L, Xiong Z
Letter: Critical appraisal of biologic therapy in management of early ulcerative colitis-Addressing study limitations and the role of psychological resilience.
Aliment Pharmacol Ther. 2024 Jul 28. doi: 10.1111/apt.18156.
PubMed

STRANDE V, Hoivik ML, Kristensen VA
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management-Addressing study limitations and the role of psychological resilience-Authors' reply.
Aliment Pharmacol Ther. 2024 Jul 28. doi: 10.1111/apt.18187.
PubMed

SCHREIBER S, Cross RK, Panaccione R, D'Haens G, et al
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease.
Aliment Pharmacol Ther. 2024 Jul 25. doi: 10.1111/apt.18184.
PubMed Abstract available

ARVANITAKIS K, Germanidis G
Editorial: GLP-1 receptor agonists in inflammatory bowel disease-Is it time?
Aliment Pharmacol Ther. 2024 Jul 21. doi: 10.1111/apt.18152.
PubMed

BOGATIC D, Bryant RV
Letter: Microbial manipulation for primary sclerosing cholangitis-associated inflammatory bowel disease-hope on the horizon.
Aliment Pharmacol Ther. 2024 Jul 16. doi: 10.1111/apt.18098.
PubMed

WEWER MD, Nordestgaard RLM, Malham M, Wewer V, et al
Editorial: Treatments of inflammatory bowel disease across age-spectrum-Are they the same? Authors' reply.
Aliment Pharmacol Ther. 2024 Jul 8. doi: 10.1111/apt.18163.
PubMed

HO AHY, Mak JWY
Editorial: Treatments for inflammatory bowel disease across the age spectrum-Are they the same?
Aliment Pharmacol Ther. 2024 Jul 8. doi: 10.1111/apt.18143.
PubMed

June 2024

DESAI A, Petrov J, Hashash JG, Patel H, et al
Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Jun 27. doi: 10.1111/apt.18138.
PubMed Abstract available

RAO V, Chen G, Koh E, Segal JP, et al
Letter: Persisting with persistence-Caution as an outcome measure in inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Jun 24. doi: 10.1111/apt.18114.
PubMed

YIU TH, Ko Y, Pudipeddi A, Natale P, et al
Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease: Authors' reply.
Aliment Pharmacol Ther. 2024 Jun 24. doi: 10.1111/apt.18136.
PubMed

BAK MTJ, Demers K, Hammoudi N, Allez M, et al
Systematic review: Patient-related, microbial, surgical, and histopathological risk factors for endoscopic post-operative recurrence in patients with Crohn's disease.
Aliment Pharmacol Ther. 2024 Jun 17. doi: 10.1111/apt.18040.
PubMed Abstract available

CHHIBBA T
Editorial: Surgery to reduce opioid use in Crohn's disease: Does a classic solution address a newer problem?
Aliment Pharmacol Ther. 2024 Jun 14. doi: 10.1111/apt.18051.
PubMed

SEO J, Kim S, Hong SW, Hwang SW, et al
Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study.
Aliment Pharmacol Ther. 2024 Jun 12. doi: 10.1111/apt.18102.
PubMed Abstract available

ATTAUABI M, Steenholdt C, Poulsen A, Gubatan J, et al
Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease.
Aliment Pharmacol Ther. 2024 Jun 11. doi: 10.1111/apt.18110.
PubMed Abstract available

NORDESTGAARD RLM, Wewer MD, Malham M, Wewer V, et al
Treatment of inflammatory bowel disease with steroid-sparing medications is age-dependent - Results from a Danish nationwide cohort study, 2000-2018.
Aliment Pharmacol Ther. 2024 Jun 10. doi: 10.1111/apt.18106.
PubMed Abstract available

FUKUDA T, Yamazaki H, Matsuoka K
Editorial: Mucosal healing with steroids-Once upon a time in ulcerative colitis. Authors' reply.
Aliment Pharmacol Ther. 2024 Jun 9. doi: 10.1111/apt.18111.
PubMed

BARREIRO-DE ACOSTA M, Rodriguez-Lago I
Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis.
Aliment Pharmacol Ther. 2024 Jun 9. doi: 10.1111/apt.18094.
PubMed

GARCIA MJ, Gisbert JP, Chaparro M
Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions-Authors' reply.
Aliment Pharmacol Ther. 2024 Jun 6. doi: 10.1111/apt.18104.
PubMed

STRANDE V, Lund C, Hagen M, Bengtson MB, et al
Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort.
Aliment Pharmacol Ther. 2024 Jun 4. doi: 10.1111/apt.18097.
PubMed Abstract available

CHETWOOD JD, Ding NS
Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions.
Aliment Pharmacol Ther. 2024 Jun 3. doi: 10.1111/apt.18056.
PubMed

SONG S, Lv J, Li L, Pang Y, et al
Editorial: Exploring the influence of diet on later-onset ulcerative colitis-Are eggs and spicy foods the key factors in Asia? Authors' reply.
Aliment Pharmacol Ther. 2024;59:1453-1454.
PubMed

ALIU A, Bosch DHCA, Keszthelyi D, Ardabili AR, et al
Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD-Authors' reply.
Aliment Pharmacol Ther. 2024;59:1646-1647.
PubMed

LEONG RW, Jairath V, Ma C
Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD.
Aliment Pharmacol Ther. 2024;59:1644-1645.
PubMed

BEATON D, Sharp L, Lu L, Trudgill N, et al
Diagnostic yield from symptomatic lower gastrointestinal endoscopy in the UK: A British Society of Gastroenterology analysis using data from the National Endoscopy Database.
Aliment Pharmacol Ther. 2024;59:1589-1603.
PubMed Abstract available

May 2024

DUTT K, Vasudevan A
Editorial: Exclusive enteral nutrition: Positioning in the ever-growing landscape of inflammatory bowel disease therapy.
Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18055.
PubMed

ALAHMAD M, Quraishi MN, Khan SW, Omar NM, et al
Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease.
Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18049.
PubMed

YIU TH, Ko Y, Pudipeddi A, Natale P, et al
Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply.
Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18057.
PubMed

VUIJK SA, de Ridder L
Editorial: Infliximab induction therapy in paediatric Crohn's disease: A cost-effective strategy? Authors' reply.
Aliment Pharmacol Ther. 2024 May 21. doi: 10.1111/apt.18053.
PubMed

CHANCHLANI N, Russell RK
Editorial: Infliximab induction therapy in pediatric Crohn's disease-A cost-effective strategy?
Aliment Pharmacol Ther. 2024 May 21. doi: 10.1111/apt.18033.
PubMed

PLOTKIN L, Buchuk R, Lujan R, Focht G, et al
Enteral nutrition compared with corticosteroids in children with Crohn's disease: A long-term nationwide study from the epi-IIRN.
Aliment Pharmacol Ther. 2024 May 14. doi: 10.1111/apt.18028.
PubMed Abstract available

NEDUMANNIL L, Mohamedrashed M, Bohra A, Sood S, et al
Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease.
Aliment Pharmacol Ther. 2024;59:1162-1163.
PubMed

BARTH I, Stevens CL, Strokap CJ, Campmans-Kuijpers MJE, et al
Letter: Diet-microbiome interactions in inflammatory bowel disease-Navigating towards individualised dietary strategies.
Aliment Pharmacol Ther. 2024;59:1154-1155.
PubMed

THWAITES PA, Gibson PR
Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease. Authors' reply.
Aliment Pharmacol Ther. 2024;59:1164-1165.
PubMed

SEIDELIN JB
Editorial: Time to address quality of life in our IBD treatment-IBD nurse intervention as a key part of multimodal IBD management.
Aliment Pharmacol Ther. 2024;59:1152-1153.
PubMed

GARCIA MJ, Gisbert JP, Chaparro M
Editorial: Sequencing rescue therapy for acute severe ulcerative colitis-Ready for revision? Authors' reply.
Aliment Pharmacol Ther. 2024;59:1298-1299.
PubMed

DERIKX LAAP, Hoentjen F
Editorial: Sequencing rescue therapy for acute severe ulcerative colitis-Ready for revision?
Aliment Pharmacol Ther. 2024;59:1296-1297.
PubMed

SHAH A, Holtmann G
Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis-associated inflammatory bowel disease?
Aliment Pharmacol Ther. 2024;59:1290-1291.
PubMed

NORGARD BM, Thorarinsson CT, Zegers FD, Kjeldsen J, et al
The use of opioids nine months after surgery for Crohn's disease - a nationwide cohort study.
Aliment Pharmacol Ther. 2024 May 1. doi: 10.1111/apt.18014.
PubMed Abstract available

April 2024

SONG S, Wu Z, Lv J, Yu C, et al
Dietary factors and patterns in relation to risk of later-onset ulcerative colitis in Chinese: A prospective study of 0.5 million people.
Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.17963.
PubMed Abstract available

FUKUDA T, Yamazaki H, Miyatani Y, Sawada T, et al
Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing.
Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.18013.
PubMed Abstract available

YIU TH, Ko Y, Pudipeddi A, Natale P, et al
Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.18006.
PubMed Abstract available

FERNANDEZ-CLOTET A, Ordas I, Masamunt MC, Caballol B, et al
Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long-term adverse outcomes in Crohn's disease.
Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.17968.
PubMed Abstract available

VUIJK SA, Jongsma MME, Hoeven BM, Cozijnsen MA, et al
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.18000.
PubMed Abstract available

URQUHART SA, Fletcher JG, Bruining DH
Editorial: Foretelling the future-Emerging role of magnetic resonance enterography as a prognostic tool in Crohn's disease.
Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17991.
PubMed

OKABAYASHI S, Kobayashi T
Editorial: Exploring the influence of diet on later-onset ulcerative colitis-Are eggs and spicy foods the key factors in Asia?
Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17983.
PubMed

ARATARI A, Scribano ML, Pugliese D, Baccolini V, et al
Crohn's disease after surgery: Changes in post-operative management strategies over time and their impact on long-term re-operation rate-A retrospective multicentre real-world study.
Aliment Pharmacol Ther. 2024 Apr 14. doi: 10.1111/apt.18001.
PubMed Abstract available

KIM K, Park JJ, Yoon H, Lee J, et al
Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study.
Aliment Pharmacol Ther. 2024 Apr 14. doi: 10.1111/apt.17989.
PubMed Abstract available

ALIU A, Bosch DHCA, Keszthelyi D, Rezazadeh Ardabili A, et al
Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission.
Aliment Pharmacol Ther. 2024 Apr 8. doi: 10.1111/apt.17988.
PubMed Abstract available

VASUDEVAN A, Con D, van Langenberg DR
Letter: Thioguanine, an under-utilised option in inflammatory bowel disease? Authors' reply.
Aliment Pharmacol Ther. 2024;59:1011.
PubMed

ASONUMA K, Sagami S, Kobayashi T
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights.
Aliment Pharmacol Ther. 2024;59:1005-1006.
PubMed

CHETWOOD JD, Paramsothy S, Leong RW
Letter: Thioguanine, an underutilised option in inflammatory bowel disease?
Aliment Pharmacol Ther. 2024;59:1009-1010.
PubMed

March 2024

AKIYAMA S, Yokoyama K, Yagi S, Shinzaki S, et al
Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan.
Aliment Pharmacol Ther. 2024 Mar 17. doi: 10.1111/apt.17961.
PubMed Abstract available

RICCIUTO A, Liu K, El-Matary W, Amin M, et al
Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.
Aliment Pharmacol Ther. 2024 Mar 10. doi: 10.1111/apt.17936.
PubMed Abstract available

GARCIA MJ, Riestra S, Amiot A, Julsgaard M, et al
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
Aliment Pharmacol Ther. 2024 Mar 6. doi: 10.1111/apt.17938.
PubMed Abstract available

LU C, Rosentreter R, Delisle M, White M, et al
Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound.
Aliment Pharmacol Ther. 2024 Mar 4. doi: 10.1111/apt.17918.
PubMed Abstract available

GONCZI L, Lakatos L, Ilias A, Lakatos PL, et al
Editorial: The prevalence and outcomes of perianal Crohn's disease across the treatment eras-Authors' reply.
Aliment Pharmacol Ther. 2024;59:715-716.
PubMed

LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply.
Aliment Pharmacol Ther. 2024;59:723-724.
PubMed

LAHARIE D
Letter: Should ulcerative colitis be monitored more or less invasively?
Aliment Pharmacol Ther. 2024;59:721-722.
PubMed

TASSONE D, Hartley I, Ding NS
Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras.
Aliment Pharmacol Ther. 2024;59:713-714.
PubMed

VAN LIERE ELSA, de Boer NKH
Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease.
Aliment Pharmacol Ther. 2024;59:792-793.
PubMed

VASUDEVAN A, Con D, van Langenberg DR
Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2024;59:794.
PubMed

BOKEMEYER B, Plachta-Danielzik S, Steiner IM, Pohlschneider D, et al
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD(BIO-ASSIST) study).
Aliment Pharmacol Ther. 2024 Mar 1. doi: 10.1111/apt.17926.
PubMed Abstract available

February 2024

ERIKSSON C, Sun J, Bryder M, Broms G, et al
Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study.
Aliment Pharmacol Ther. 2024 Feb 29. doi: 10.1111/apt.17932.
PubMed Abstract available

ZAMANI M, Alizadeh-Tabari S, Murad MH, Ananthakrishnan AN, et al
Meta-analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Feb 19. doi: 10.1111/apt.17919.
PubMed Abstract available

SAGAMI S, Kobayashi T
Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety.
Aliment Pharmacol Ther. 2024;59:579-580.
PubMed

PANACCIONE R
Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author's reply.
Aliment Pharmacol Ther. 2024;59:581-582.
PubMed

VASUDEVAN A, Con D, De Cruz P, Sparrow MP, et al
Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study).
Aliment Pharmacol Ther. 2024;59:504-514.
PubMed Abstract available

January 2024

CON D, Srinivasan A
Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug.
Aliment Pharmacol Ther. 2024;59:140-141.
PubMed

VAN DE MEEBERG MM, Fidder HH, de Jonge R, Bouma G, et al
Editorial: Monitoring methotrexate polyglutamates in Crohn's disease-Authors' reply.
Aliment Pharmacol Ther. 2024;59:120-121.
PubMed

BARCLAY ML, Stamp LK
Editorial: Monitoring methotrexate polyglutamates in Crohn's disease.
Aliment Pharmacol Ther. 2024;59:118-119.
PubMed

PRAY C, Narula N
Editorial: Moving towards prognostic endoscopic scoring in IBD.
Aliment Pharmacol Ther. 2024;59:132-133.
PubMed

December 2023

GONCZI L, Lakatos L, Golovics PA, Angyal D, et al
Burden of perianal disease in Crohn's disease: Accelerating medical therapy and high rates of perianal surgery over the last four decades - Results from a population-based study over four decades.
Aliment Pharmacol Ther. 2023 Dec 19. doi: 10.1111/apt.17836.
PubMed Abstract available

MEYER A, Dong C, Chan SSM, Touvier M, et al
Dietary index based on the Food Standards Agency nutrient profiling system and risk of Crohn's disease and ulcerative colitis.
Aliment Pharmacol Ther. 2023 Dec 15. doi: 10.1111/apt.17835.
PubMed Abstract available

DESAI A, Regueiro M, Kochhar GS
Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply.
Aliment Pharmacol Ther. 2023;58.
PubMed

SOHN J
Editorial: Unravelling the relationship between periodontal disease and inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;58.
PubMed

REZAZADEH ARDABILI A, Janssen L, Mujagic Z
Letter: Abdominal pain in patients with inflammatory bowel disease in remission - A look beyond psychosocial factors. Authors' reply.
Aliment Pharmacol Ther. 2023;58.
PubMed

CHANG HC, Gau SY
Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis.
Aliment Pharmacol Ther. 2023;58.
PubMed

BASSOTTI G, Villanacci V, Maconi G
Letter: Abdominal pain in inflammatory bowel disease patients in remission-A look beyond psychosocial factors.
Aliment Pharmacol Ther. 2023;58.
PubMed

November 2023

BUISSON A, Nachury M, Bazoge M, Yzet C, et al
Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study.
Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17822.
PubMed Abstract available

PEYRIN-BIROULET L, Vermeire S, D'Haens G, Panes J, et al
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17751.
PubMed Abstract available

PANACCIONE R, Danese S, Zhou W, Klaff J, et al
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
Aliment Pharmacol Ther. 2023 Nov 27. doi: 10.1111/apt.17816.
PubMed Abstract available

BOKEMEYER B, Plachta-Danielzik S
Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-It depends on how you use the drug. Authors' reply.
Aliment Pharmacol Ther. 2023 Nov 4. doi: 10.1111/apt.17796.
PubMed

KELLER JJ, Terveer EM
Editorial: Continuous monitoring to improve outcome of treatment-the next step towards safe and effective faecal microbiota transplantation.
Aliment Pharmacol Ther. 2023;58:946-947.
PubMed

DAN L, Wang X, Chen J
Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD. Authors' reply.
Aliment Pharmacol Ther. 2023;58:940-941.
PubMed

LOPES EW, Khalili H
Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD.
Aliment Pharmacol Ther. 2023;58:938-939.
PubMed

October 2023

SPARTZ EJ, DeDecker LC, Fansiwala KM, Noorian S, et al
Recent trends and risk factors associated with Clostridioides difficile infections in hospitalized patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Oct 24. doi: 10.1111/apt.17777.
PubMed Abstract available

LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis.
Aliment Pharmacol Ther. 2023 Oct 16. doi: 10.1111/apt.17753.
PubMed Abstract available

DAJTI E, Frazzoni L, Iascone V, Secco M, et al
Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
Aliment Pharmacol Ther. 2023 Oct 12. doi: 10.1111/apt.17754.
PubMed Abstract available

KAYAL M, Meringer H, Martin L, Colombel JF, et al
Scores used to predict outcomes in acute severe ulcerative colitis: A systematic review.
Aliment Pharmacol Ther. 2023 Oct 11. doi: 10.1111/apt.17731.
PubMed Abstract available

RIGGOTT C, Fairbrass KM, Black CJ, Gracie DJ, et al
Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study.
Aliment Pharmacol Ther. 2023 Oct 4. doi: 10.1111/apt.17735.
PubMed Abstract available

WILLIAMS KM, Challa PK, Lopes EW, Burke KE, et al
Periodontal disease is not associated with risk of inflammatory bowel disease: Results from two prospective cohort studies in the US.
Aliment Pharmacol Ther. 2023 Oct 2. doi: 10.1111/apt.17732.
PubMed Abstract available

TASSONE D, Hartley I, Ding NS
Letter: Muscle thickness measurement using ultrasound-A step closer to the use of body composition analysis in the management of inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;58:729-730.
PubMed

ANDREW B, Zhou A, Trinh S, Srinivasan A, et al
Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed.
Aliment Pharmacol Ther. 2023;58:838-839.
PubMed

OH SJ, Kim HJ, Lee CK
Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed-Authors' reply.
Aliment Pharmacol Ther. 2023;58:840-841.
PubMed

ARULJOTHY A, Singh S, Narula N, Moran GW, et al
Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
Aliment Pharmacol Ther. 2023;58:740-762.
PubMed Abstract available

REZAZADEH ARDABILI A, Van Bodegraven AA
Editorial: IBD cost evolution - transitioning from compensating lost productivity to escalating medication expenses.
Aliment Pharmacol Ther. 2023;58:832-833.
PubMed

September 2023

VAN DE MEEBERG MM, Fidder HH, Oldenburg B, Sundaresan J, et al
Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.
Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17719.
PubMed Abstract available

FAQERAH N, Walker D, Gerasimidis K
Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17720.
PubMed Abstract available

JANSSEN LM, Rezazadeh Ardabili A, Romberg-Camps MJL, Winkens B, et al
Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors.
Aliment Pharmacol Ther. 2023 Sep 19. doi: 10.1111/apt.17718.
PubMed Abstract available

SCHREIBER S, Rogler G, Watanabe M, Vermeire S, et al
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.
Aliment Pharmacol Ther. 2023 Sep 18. doi: 10.1111/apt.17674.
PubMed Abstract available

ANDREW B, Srinivasan A, Zhou A, Vasudevan A, et al
Letter: Elderly onset inflammatory bowel disease-Treat to target approach is still warranted.
Aliment Pharmacol Ther. 2023;58:556-557.
PubMed

YAMAMOTO T
Editorial: Is vedolizumab the preferred biologic therapy for biologic-naive patients with ulcerative colitis?
Aliment Pharmacol Ther. 2023;58:546-547.
PubMed

DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges.
Aliment Pharmacol Ther. 2023;58:492-502.
PubMed Abstract available

WU X, Yang Y
Letter: Chinese herbal medicine Curcumin-QingDai (CurQD) - A good treatment option for active ulcerative colitis?
Aliment Pharmacol Ther. 2023;58:640.
PubMed

DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails-Authors' reply.
Aliment Pharmacol Ther. 2023;58:634-635.
PubMed

KEDIA S, Ahuja V
Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails.
Aliment Pharmacol Ther. 2023;58:632-633.
PubMed

YANAI H, Salomon N, Ben-Horin S, Kopylov U, et al
Letter: Chinese herbal medicine Curcumin-QingDai (CurQD)-A good treatment option for active ulcerative colitis? Authors' reply.
Aliment Pharmacol Ther. 2023;58:641.
PubMed

August 2023

HONAP S, Peyrin-Biroulet L
Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease?
Aliment Pharmacol Ther. 2023 Aug 21. doi: 10.1111/apt.17684.
PubMed Abstract available

EVERHOV AH, Soderling J, Befrits G, Khalili H, et al
Increasing healthcare costs in inflammatory bowel disease 2007-2020 in Sweden.
Aliment Pharmacol Ther. 2023 Aug 18. doi: 10.1111/apt.17675.
PubMed Abstract available

WOELFEL S, Dutschler J, Konig M, Dulovic A, et al
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Aug 12. doi: 10.1111/apt.17661.
PubMed Abstract available

LOBATON T, Truyens M
Editorial: LAG-3-depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?
Aliment Pharmacol Ther. 2023;58:359-360.
PubMed

KANE S
Editorial: Increased risk of cervical dysplasia with immunomodulator use in IBD.
Aliment Pharmacol Ther. 2023;58:357-358.
PubMed

KIRCHGESNER J, Beaugerie L
Editorial: Pip pip to PIPs (post- inflammatory polyps) as a neoplasia risk factor in IBD? Authors' reply.
Aliment Pharmacol Ther. 2023;58:363.
PubMed

TASSONE D, Hartley I, Ding NS
Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;58:376-377.
PubMed

VELAYOS FS
Editorial: Pip pip to PIP's (post-inflammatory polyps) as a neoplasia risk factor in IBD?
Aliment Pharmacol Ther. 2023;58:361-362.
PubMed

July 2023

DENG M, Dan L, Ye S, Chen X, et al
Higher dietary fibre intake is associated with lower risk of inflammatory bowel disease: prospective cohort study.
Aliment Pharmacol Ther. 2023 Jul 18. doi: 10.1111/apt.17649.
PubMed Abstract available

MIN Y, Wei X, Peng X
Letter: Mendelian randomization-New perspective in inflammatory bowel disease and pancreatic cancer?
Aliment Pharmacol Ther. 2023;58:143-144.
PubMed

MASSIRONI S, Vigano C, Danese S
Letter: Mendelian randomization - new perspective in inflammatory bowel disease and pancreatic cancer? Authors' reply.
Aliment Pharmacol Ther. 2023;58:145-146.
PubMed

MILES M, Nasser Y
Editorial: faecal incontinence in ulcerative colitis.
Aliment Pharmacol Ther. 2023;58:114-115.
PubMed

CHAN P, Connor S, Huang V, Karimi N, et al
Letter: expanding the role for decision aids in IBD into pregnancy-related topics.
Aliment Pharmacol Ther. 2023;58:141-142.
PubMed

ESTEVINHO MM, Magro F
Editorial: elderly onset inflammatory bowel disease - clues from the largest population-based cohort study.
Aliment Pharmacol Ther. 2023;58:116-117.
PubMed

HUDSON AS, Huynh HQ
Editorial: Predicting paediatric ulcerative colitis outcomes-how can we improve?
Aliment Pharmacol Ther. 2023;58:258-259.
PubMed

OH SJ, Kim HJ, Lee CK
Editorial: Antibiotics and risk of IBD-Can we close the books? Authors' reply.
Aliment Pharmacol Ther. 2023;58:256-257.
PubMed

EBRAHIMI F, Forss A
Editorial: Antibiotics and risk of IBD-Can we close the books?
Aliment Pharmacol Ther. 2023;58:254-255.
PubMed

BACSUR P, Ilias A, Resal T, Kata D, et al
Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary.
Aliment Pharmacol Ther. 2023;58:262-263.
PubMed

June 2023

D'HAENS G, Peyrin-Biroulet L, Marks DJB, Lisi E, et al
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
Aliment Pharmacol Ther. 2023 Jun 16. doi: 10.1111/apt.17557.
PubMed Abstract available

BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Efken P, et al
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naive patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO(IBD) -study.
Aliment Pharmacol Ther. 2023 Jun 15. doi: 10.1111/apt.17616.
PubMed Abstract available

NGUYEN AL, Burns M, Herath M, Lambell K, et al
Accuracy of ultrasound, bioelectrical impedance analysis and anthropometry as point-of-care measurements of skeletal muscle mass in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Jun 12. doi: 10.1111/apt.17607.
PubMed Abstract available

KOCHHAR GS, Desai A, Farraye FA, Cross RK, et al
Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study.
Aliment Pharmacol Ther. 2023 Jun 9. doi: 10.1111/apt.17570.
PubMed Abstract available

MACALUSO FS, Orlando A
Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation?
Aliment Pharmacol Ther. 2023;57:1343-1344.
PubMed

CALDERA F, Spaulding AC, Hayney MS, Farraye FA, et al
Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation? Authors' reply.
Aliment Pharmacol Ther. 2023;57:1345-1346.
PubMed

CHEN P, Chen F
Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients.
Aliment Pharmacol Ther. 2023;57:1349-1350.
PubMed

IKEGAMI S, Nakamura M, Honda T, Kawashima H, et al
Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients-authors' reply.
Aliment Pharmacol Ther. 2023;57:1351-1352.
PubMed

HANZEL J, Drobne D
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring.
Aliment Pharmacol Ther. 2023;57:1469-1470.
PubMed

SETHI S, Kumar A, Dias S, Blackwell J, et al
Editorial: proactive anti-TNF drug monitoring in IBD-Ready for the prime time? Authors' reply.
Aliment Pharmacol Ther. 2023;57:1455-1456.
PubMed

FUMERY M, Roblin X
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's reply.
Aliment Pharmacol Ther. 2023;57:1471-1472.
PubMed

ROBLIN X, Nancey S
Editorial: proactive anti-TNF drug monitoring in IBD-Ready for prime time?
Aliment Pharmacol Ther. 2023;57:1453-1454.
PubMed

POLLOK RC, Jayasooriya N, Baillie S, Blackwell J, et al
Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach. Authors' reply.
Aliment Pharmacol Ther. 2023;57:1479.
PubMed

CHANG HC, Gau SY
Letter: histologic disease activity and colorectal neoplasia risk.
Aliment Pharmacol Ther. 2023;57:1480.
PubMed

LUCAS S, Chauhan A, Garg M
Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach.
Aliment Pharmacol Ther. 2023;57:1477-1478.
PubMed

May 2023

ATIA O, Klomberg RCW, de Ridder L, Kemos P, et al
Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort.
Aliment Pharmacol Ther. 2023 May 29. doi: 10.1111/apt.17544.
PubMed Abstract available

KREIJNE JE, Goetgebuer RL, Erler NS, De Boer NK, et al
Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 May 23. doi: 10.1111/apt.17555.
PubMed Abstract available

YANAI H, Salomon N, Lahat A, Ungar B, et al
Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study.
Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17538.
PubMed Abstract available

OH SJ, Kim HJ, Lee CK
A dose-dependent increase in the risk of inflammatory bowel disease after exposure to broad-spectrum antibiotics: A national population study in Korea.
Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17542.
PubMed Abstract available

CHEN J, Ruan X, Yuan S, Theodoratou E, et al
Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation-authors' reply.
Aliment Pharmacol Ther. 2023;57:1034-1035.
PubMed

VAN RULER O, Arkenbosch JHC, van der Woude CJ
Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease. Authors' reply.
Aliment Pharmacol Ther. 2023;57:1030-1031.
PubMed

BURISCH J
Editorial: Why are patients with Crohn's disease still treated with 5-aminosalicylates?
Aliment Pharmacol Ther. 2023;57:1044-1045.
PubMed

DART RJ
Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease.
Aliment Pharmacol Ther. 2023;57:1028-1029.
PubMed

MEYER A, Amiot A, Carbonnel F
Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation.
Aliment Pharmacol Ther. 2023;57:1032-1033.
PubMed

CHEN J, Ruan X, Yuan S, Theodoratou E, et al
Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases-moving towards causal associations. Authors' reply.
Aliment Pharmacol Ther. 2023;57:1048-1049.
PubMed

GEERTSEMA S, van Goor H, Dijkstra G, Faber KN, et al
Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases - moving towards causal associations.
Aliment Pharmacol Ther. 2023;57:1046-1047.
PubMed

SONNENBERG A, Genta RM
Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter? Authors' reply.
Aliment Pharmacol Ther. 2023;57:1155-1156.
PubMed

SZIGETI R, Krishna M, Kellermayer R
Letter: fulminant-onset complicated inflammatory bowel disease (IBD)-a unique subtype?
Aliment Pharmacol Ther. 2023;57:1192-1193.
PubMed

POLLOK RC, Baillie S, Jayasooriya N, Blackwell J, et al
Letter: diagnostic delay in inflammatory bowel disease-Authors' reply.
Aliment Pharmacol Ther. 2023;57:1205-1206.
PubMed

ATIA O, Goren I, Yanai H
Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease-authors' reply.
Aliment Pharmacol Ther. 2023;57:1184-1185.
PubMed

ANDERSON RP
Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter?
Aliment Pharmacol Ther. 2023;57:1153-1154.
PubMed

TASSONE D, Gilmore R, Lee T, Ding NS, et al
Letter: diagnostic delay in inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;57:1203-1204.
PubMed

JAYASOORIYA N, Saxena S, Pollok RC
Letter: fulminant onset complicated inflammatory bowel disease (IBD) - a unique subtype? Authors' reply.
Aliment Pharmacol Ther. 2023;57:1194-1195.
PubMed

CHANG HC, Gau SY
Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease.
Aliment Pharmacol Ther. 2023;57:1183.
PubMed

April 2023

CASANOVA MJ, Nantes O, Varela P, Vela-Gonzalez M, et al
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
Aliment Pharmacol Ther. 2023 Apr 23. doi: 10.1111/apt.17525.
PubMed Abstract available

NORGARD BM, Zegers FD, Knudsen T, Kjeldsen J, et al
Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study.
Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17520.
PubMed Abstract available

BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Helwig U, et al
Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study.
Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17512.
PubMed Abstract available

GOLD SL, Raman M, Sands BE, Ungaro R, et al
Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17498.
PubMed Abstract available

OLIVERA PA, Lasa JS, Peretto G, Zuily S, et al
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
Aliment Pharmacol Ther. 2023 Apr 10. doi: 10.1111/apt.17509.
PubMed Abstract available

VASANT DH, Nigam GB, Bate S, Hamdy S, et al
The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross-sectional study.
Aliment Pharmacol Ther. 2023 Apr 3. doi: 10.1111/apt.17502.
PubMed Abstract available

GUPTA A, Kedia S, Ahuja V
Letter: trial of antitubercular therapy for diagnosing Crohn's disease in LMICs-double whammy?
Aliment Pharmacol Ther. 2023;57:815-816.
PubMed

SPEEDY AP, Wall CL
Editorial: Interdisciplinary and multidisciplinary approach to malnutrition in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;57:907-908.
PubMed

March 2023

WOLF T, Lewis A, Beaugerie L, Svrcek M, et al
Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post-inflammatory polyps.
Aliment Pharmacol Ther. 2023 Mar 31. doi: 10.1111/apt.17495.
PubMed Abstract available

CALDERA F, Spaulding AC, Borah B, Moriarty J, et al
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Mar 10. doi: 10.1111/apt.17454.
PubMed Abstract available

ATIA O, Goren I, Fischler TS, Weisband YL, et al
5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study.
Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17419.
PubMed Abstract available

MELTON SL, Taylor KM, Gibson PR, Halmos EP, et al
Review article: Mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn's disease.
Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17451.
PubMed Abstract available

CHANG HC, Gau SY
Letter: sleep duration and the incidence of inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;57:595-596.
PubMed

COLMAN RJ, Minar P
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2023;57:567-568.
PubMed

HORSFALL E, Irwin J
Editorial: inflammatory bowel disease and sleep.
Aliment Pharmacol Ther. 2023;57:573-574.
PubMed

CORTESI PA, Fiorino G, Mantovani LG, Danese S, et al
Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay? Authors' reply.
Aliment Pharmacol Ther. 2023;57:571-572.
PubMed

BARBER GE, Gubatan J
Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay?
Aliment Pharmacol Ther. 2023;57:569-570.
PubMed

YUAN S, Chen J, Li X
Editorial: IBD and sleep-authors' reply.
Aliment Pharmacol Ther. 2023;57:575-576.
PubMed

VUIJK SA, de Ridder L
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;57:565-566.
PubMed

PEYRIN-BIROULET L, Ghosh S, Lee SD, Lee WJ, et al
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
Aliment Pharmacol Ther. 2023;57:496-508.
PubMed Abstract available

BUISSON A
Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure? Authors' reply.
Aliment Pharmacol Ther. 2023;57:735-736.
PubMed

VOLKERS A, Straatmijer T, Duijvestein M, Lowenberg M, et al
Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply.
Aliment Pharmacol Ther. 2023;57:743-744.
PubMed

ERNEST-SUAREZ K, Lu C
Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure?
Aliment Pharmacol Ther. 2023;57:733-734.
PubMed

RICHARD N, Vuitton L, Fumery M
Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;57:741-742.
PubMed

February 2023

FUMERY M, Nancey S, Filippi J, Altwegg R, et al
Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.
Aliment Pharmacol Ther. 2023 Feb 27. doi: 10.1111/apt.17421.
PubMed Abstract available

REGEV S, Schwartz D, Sarid O, Goren G, et al
Randomised clinical trial: Psychological intervention improves work productivity and daily activity by reducing abdominal pain and fatigue in Crohn's disease.
Aliment Pharmacol Ther. 2023 Feb 2. doi: 10.1111/apt.17399.
PubMed Abstract available

SONNENBERG A, Genta RM
Case-control study of the concurrence of coeliac disease with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Feb 2. doi: 10.1111/apt.17408.
PubMed Abstract available

CHOWDHURY R, Kane SV
Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease-a Danish cohort study.
Aliment Pharmacol Ther. 2023;57:349-350.
PubMed

VESTERGAARD T, Kelsen J, Julsgaard M
Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease - a Danish cohort study. Authors' reply.
Aliment Pharmacol Ther. 2023;57:351-352.
PubMed

January 2023

CHEN J, Ruan X, Yuan S, Deng M, et al
Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study.
Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17392.
PubMed Abstract available

TAXONERA C, Olivares D, Lopez-Garcia ON, Alba C, et al
Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17386.
PubMed Abstract available

KHAN N, Mahmud N, Patel M, Sundararajan R, et al
Risk of severe and opportunistic infections and the impact of SARS-COV-2 on this risk in a nationwide cohort of patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17393.
PubMed Abstract available

IKEGAMI S, Nakamura M, Honda T, Yamamura T, et al
Efficacy of 1-kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double-blind, placebo-controlled pilot study.
Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17387.
PubMed Abstract available

DUA A, Corson M, Sauk JS, Jaffe N, et al
Impact of malnutrition and nutrition support in hospitalised patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Jan 13. doi: 10.1111/apt.17389.
PubMed Abstract available

JAYASOORIYA N, Baillie S, Blackwell J, Bottle A, et al
Systematic review with meta-analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Jan 10. doi: 10.1111/apt.17370.
PubMed Abstract available

LAHARIE D, Riviere P
Editorial: selecting therapy for ulcerative colitis-think a step ahead.
Aliment Pharmacol Ther. 2023;57:161-162.
PubMed

WOELFEL S, Dutschler J, Konig M, Graf N, et al
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Aliment Pharmacol Ther. 2023;57:103-116.
PubMed Abstract available

REIJNTJES MA, de Voogd FAE, Buskens CJ, Gecse KB, et al
Editorial: routine use of intestinal ultrasound in ulcerative colitis-are we missing the appendix? Authors' reply.
Aliment Pharmacol Ther. 2023;57:255-256.
PubMed

SCRIBANO ML
Editorial: shared decision-making intervention in patients with Crohn's disease-a personalised, patient-centred approach.
Aliment Pharmacol Ther. 2023;57:263-264.
PubMed

ERNEST-SUAREZ K, Novak K
Editorial: routine use of intestinal ultrasound in ulcerative colitis-are we missing the appendix?
Aliment Pharmacol Ther. 2023;57:253-254.
PubMed

LIWINSKI T, Hubener S, Henze L, Hubener P, et al
A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis.
Aliment Pharmacol Ther. 2023;57:224-236.
PubMed Abstract available

December 2022

DIN S, Selinger CP, Black CJ, Ford AC, et al
Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Dec 31. doi: 10.1111/apt.17379.
PubMed Abstract available

ARKENBOSCH JHC, van Ruler O, Dwarkasing RS, Fuhler GM, et al
Stromal vascular fraction with platelet-rich plasma injection during surgery is feasible and safe in treatment-refractory perianal fistulising Crohn's disease: A pilot study.
Aliment Pharmacol Ther. 2022 Dec 26. doi: 10.1111/apt.17347.
PubMed Abstract available

FUMERY M, Defrance A, Roblin X, Altwegg R, et al
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
Aliment Pharmacol Ther. 2022 Dec 19. doi: 10.1111/apt.17358.
PubMed Abstract available

VESTERGAARD T, Julsgaard M, Rosok JF, Vestergaard SV, et al
Predictors of disease activity during pregnancy in women with inflammatory bowel disease-a Danish cohort study.
Aliment Pharmacol Ther. 2022 Dec 14. doi: 10.1111/apt.17348.
PubMed Abstract available

SETHI S, Dias S, Kumar A, Blackwell J, et al
Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Dec 9. doi: 10.1111/apt.17313.
PubMed Abstract available

VUIJK SA, de Ridder L
Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease.
Aliment Pharmacol Ther. 2022;56.
PubMed

KULYK A, Shafer LA, Graff LA, Stone J, et al
Urgency for bowel movements is a highly discriminatory symptom of active disease in persons with IBD (the Manitoba Living with IBD study).
Aliment Pharmacol Ther. 2022;56.
PubMed Abstract available

November 2022

BUISSON A, Nachury M, Guilmoteau T, Altwegg R, et al
Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
Aliment Pharmacol Ther. 2022 Nov 19. doi: 10.1111/apt.17305.
PubMed Abstract available

CORTESI PA, Fiorino G, Peyrin-Biroulet L, Mantovani LG, et al
Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis.
Aliment Pharmacol Ther. 2022 Nov 15. doi: 10.1111/apt.17261.
PubMed Abstract available

ZISMAN-ILANI Y, Thompson KD, Siegel LS, Mackenzie T, et al
Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial.
Aliment Pharmacol Ther. 2022 Nov 14. doi: 10.1111/apt.17286.
PubMed Abstract available

YUAN S, Sun Y, Tan X, Geng J, et al
Sleep duration and daytime napping in relation to incident inflammatory bowel disease: a prospective cohort study.
Aliment Pharmacol Ther. 2022 Nov 9. doi: 10.1111/apt.17285.
PubMed Abstract available

EVERHOV AH, Olen O
Editorial: colorectal cancer in elderly-onset IBD-what is the risk? Authors' reply.
Aliment Pharmacol Ther. 2022;56:1423-1424.
PubMed

WEISS A, Buchner AM
Editorial: colorectal cancer in elderly-onset inflammatory bowel disease-what is the risk?
Aliment Pharmacol Ther. 2022;56:1421-1422.
PubMed

LEE KE, Faye AS
Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism. Authors' reply.
Aliment Pharmacol Ther. 2022;56:1427-1428.
PubMed

SAHYOUN L, Dahiya DS, Cheng CI, Sultan K, et al
Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism.
Aliment Pharmacol Ther. 2022;56:1425-1426.
PubMed

BEZZIO C, Alimenti E, Saibeni S
Letter: immune-mediated inflammatory diseases and inflammatory bowel disease-are we ready for a Copernican revolution?
Aliment Pharmacol Ther. 2022;56:1429-1430.
PubMed

DAHL EK, Abed OK, Kjeldsen J, Donia M, et al
Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis.
Aliment Pharmacol Ther. 2022;56:1370-1382.
PubMed Abstract available

NORGARD BM, Friedman S, Kjeldsen J, Nielsen J, et al
The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study.
Aliment Pharmacol Ther. 2022;56:1349-1360.
PubMed Abstract available

RONNOW SAND J, Troelsen FS, Horvath-Puho E, Henderson VW, et al
Letter: comedication use and dementia risk in patients with inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2022;56:1505-1506.
PubMed

CHANG HC, Gau SY
Letter: comedication use and dementia risk in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2022;56:1503-1504.
PubMed

REIJNTJES MA, de Voogd FAE, Bemelman WA, Hompes R, et al
Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls - a prospective cohort study.
Aliment Pharmacol Ther. 2022 Nov 1. doi: 10.1111/apt.17267.
PubMed Abstract available

October 2022

COLMAN RJ, Mizuno T, Fukushima K, Haslam DB, et al
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance.
Aliment Pharmacol Ther. 2022 Oct 31. doi: 10.1111/apt.17277.
PubMed Abstract available

STRAATMIJER T, van Schaik FDM, Bodelier AGL, Visschedijk M, et al
Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.
Aliment Pharmacol Ther. 2022 Oct 25. doi: 10.1111/apt.17248.
PubMed Abstract available

SAIFUDDIN A, Kent AJ, Mehta SJ, Hicks LC, et al
Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
Aliment Pharmacol Ther. 2022 Oct 5. doi: 10.1111/apt.17223.
PubMed Abstract available

BURGESS CJ, Jackson R, Chalmers I, Russell RK, et al
The inexorable increase of biological exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study.
Aliment Pharmacol Ther. 2022 Oct 4. doi: 10.1111/apt.17217.
PubMed Abstract available

BURISCH J
Editorial: trends in the epidemiology of inflammatory bowel disease in Korea.
Aliment Pharmacol Ther. 2022;56:1207-1208.
PubMed

BODGER K
Editorial: rising rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease in the USA.
Aliment Pharmacol Ther. 2022;56:1211-1212.
PubMed

SHIM JO
Editorial: trends in the epidemiology of inflammatory bowel disease in Korea - author's reply.
Aliment Pharmacol Ther. 2022;56:1209-1210.
PubMed

LEE KE, Faye AS
Editorial: rising rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease in the USA-authors' reply.
Aliment Pharmacol Ther. 2022;56:1213-1214.
PubMed

CHOI SY, Kim ES, Jeon TY, Lee YM, et al
Transmural healing evaluated by magnetic resonance enterography in paediatric patients with Crohn's disease receiving maintenance treatment with biologics.
Aliment Pharmacol Ther. 2022;56:1146-1156.
PubMed Abstract available

SHIN A
Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022;56:1300-1301.
PubMed

FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2022;56:1302-1303.
PubMed

September 2022

AVNI-BIRON I, Mishael T, Zittan E, Livne-Margolin M, et al
Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study.
Aliment Pharmacol Ther. 2022 Sep 27. doi: 10.1111/apt.17224.
PubMed Abstract available

BLACK J, Sweeney L, Yuan Y, Singh H, et al
Systematic review: the role of psychological stress in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Sep 8. doi: 10.1111/apt.17202.
PubMed Abstract available

ROSIOU K, Selinger CP
Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2022;56:898-899.
PubMed

HAYDEK JP, Scott FI
Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with IBD.
Aliment Pharmacol Ther. 2022;56:896-897.
PubMed

BERTANI L, Trico D
Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue.
Aliment Pharmacol Ther. 2022;56:903-904.
PubMed

HUDSON AS, Wine E
Editorial: further support for exclusive enteral nutrition in paediatric Crohn's disease.
Aliment Pharmacol Ther. 2022;56:900-901.
PubMed

KANE S
Editorial: paternal use of IBD therapies and risk of infant infection.
Aliment Pharmacol Ther. 2022;56:902.
PubMed

LIN S, Chanchlani N, Carbery I, Janjua M, et al
Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naive patients with active luminal Crohn's disease?
Aliment Pharmacol Ther. 2022;56:783-793.
PubMed Abstract available

ATIA O, Pujol-Muncunill G, Navas-Lopez VM, Orlanski-Meyer E, et al
Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix.
Aliment Pharmacol Ther. 2022;56:794-801.
PubMed Abstract available

LIMA CCG, Peerani F
Editorial: IBD and the risk of dementia - the jury is still out.
Aliment Pharmacol Ther. 2022;56:1078-1079.
PubMed

LOPES EW, Khalili H
Editorial: investigating the association between sweetened beverages and risk of inflammatory bowel disease.
Aliment Pharmacol Ther. 2022;56:1086-1087.
PubMed

FU T, Wang X, Chen J
Editorial: investigating the association between sweetened beverages and risk of inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2022;56:1088-1089.
PubMed

HENDERSON P
Editorial: earning potential in paediatric-onset IBD-a complex interplay.
Aliment Pharmacol Ther. 2022;56:1084-1085.
PubMed

ZHAO M, Lirhus S, Lordal M, Langholz E, et al
Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
Aliment Pharmacol Ther. 2022;56:989-1006.
PubMed Abstract available

VOLKERS A, Straatmijer T, Duijvestein M, Sales A, et al
Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Aliment Pharmacol Ther. 2022;56:1044-1054.
PubMed Abstract available

August 2022

CHANCHLANI N, Lin S, Auth MK, Lee CL, et al
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
Aliment Pharmacol Ther. 2022 Aug 29. doi: 10.1111/apt.17170.
PubMed Abstract available

FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up.
Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17193.
PubMed Abstract available

IRVING PM, Leung Y, Dubinsky MC
Review article: guide to tofacitinib dosing in patients with ulcerative colitis.
Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17185.
PubMed Abstract available

MALMBORG P, Everhov AH, Soderling J, Ludvigsson JF, et al
Earnings during adulthood in patients with childhood-onset inflammatory bowel disease: A nationwide population-based cohort study.
Aliment Pharmacol Ther. 2022 Aug 2. doi: 10.1111/apt.17148.
PubMed Abstract available

EVERHOV AH, Erichsen R, Jaras J, Pedersen L, et al
Colorectal cancer in elderly-onset inflammatory bowel disease: A 1969-2017 Scandinavian register-based cohort study.
Aliment Pharmacol Ther. 2022 Aug 2. doi: 10.1111/apt.17175.
PubMed Abstract available

SOHOULI MH, Fatahi S, Farahmand F, Alimadadi H, et al
Meta-analysis: efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn's disease.
Aliment Pharmacol Ther. 2022;56:384-395.
PubMed Abstract available

TAXONERA C
Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis-Author's reply.
Aliment Pharmacol Ther. 2022;56:737-738.
PubMed

HAWTHORNE AB, Lamb CA
Editorial: quality assessment in IBD in high resource countries can lead to quality improvement clues for IBD management worldwide-authors' reply.
Aliment Pharmacol Ther. 2022;56:743.
PubMed

MANTZARIS GJ, Papamichael K
Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis.
Aliment Pharmacol Ther. 2022;56:735-736.
PubMed

PUGLIESE D, Privitera G, Armuzzi A
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' reply.
Aliment Pharmacol Ther. 2022;56:733-734.
PubMed

BERNSTEIN CN
Editorial: quality assessment in IBD in high-resource countries can lead to quality improvement clues for IBD management worldwide.
Aliment Pharmacol Ther. 2022;56:741-742.
PubMed

KEEFER L, Shapiro MJ
Editorial: measuring disease severity in inflammatory bowel disease-the whole is greater than the sum of its parts.
Aliment Pharmacol Ther. 2022;56:744-745.
PubMed

LEE H, Khan N
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease - the IG-IBD LIVE study.
Aliment Pharmacol Ther. 2022;56:731-732.
PubMed

GOLD SL, Raman M
Editorial: a formula shake each day keeps the complications away - the tolerability and effect of orally-delivered enteral nutrition in improving post-operative outcomes in patients with Crohn's disease.
Aliment Pharmacol Ther. 2022;56:739-740.
PubMed

SWAMINATHAN A, Mules TC, Gearry RB
Editorial: measuring disease severity in inflammatory bowel disease-the whole is greater than the sum of its parts. Authors' reply.
Aliment Pharmacol Ther. 2022;56:746-747.
PubMed

MEADE S, Patel KV, Luber RP, O'Hanlon D, et al
A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre.
Aliment Pharmacol Ther. 2022;56:646-663.
PubMed Abstract available

BOURGONJE AR, Alexdottir MS, Otten AT, Loveikyte R, et al
Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease.
Aliment Pharmacol Ther. 2022;56:675-693.
PubMed Abstract available

July 2022

FAYE AS, Lee KE, Dodson J, Chodosh J, et al
Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis.
Aliment Pharmacol Ther. 2022 Jul 25. doi: 10.1111/apt.17162.
PubMed Abstract available

FU T, Chen H, Chen X, Sun Y, et al
Sugar-sweetened beverages, artificially sweetened beverages and natural juices and risk of inflammatory bowel disease: a cohort study of 121,490 participants.
Aliment Pharmacol Ther. 2022 Jul 18. doi: 10.1111/apt.17149.
PubMed Abstract available

REZAZADEH ARDABILI A, Jeuring S, Mujagic Z, Oostenbrug L, et al
Classic drugs in the time of new drugs: Real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17128.
PubMed Abstract available

CHOE YJ, Han K, Shim JO
Treatment patterns of anti-tumour necrosis factor-alpha and prognosis of paediatric and adult-onset inflammatory bowel disease in Korea: a nationwide population-based study.
Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17125.
PubMed Abstract available

BIRON A, Beaugerie L, Chazouilleres O, Kirchgesner J, et al
Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Jul 4. doi: 10.1111/apt.17123.
PubMed Abstract available

SAND JR, Troelsen FS, Horvath-Puho E, Henderson VW, et al
Risk of dementia in patients with inflammatory bowel disease: a Danish population-based study.
Aliment Pharmacol Ther. 2022 Jul 3. doi: 10.1111/apt.17119.
PubMed Abstract available

QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
Letter: normalizing the ileoanal pouch-more than a one-step technique. Authors' reply.
Aliment Pharmacol Ther. 2022;56:176-177.
PubMed

WEST J, Card TR, Crooks CJ
Editorial: seeing the light at the end of gastroscope - complications after elective procedures are ready for NICE, bright decision aid tools - authors' reply.
Aliment Pharmacol Ther. 2022;56:157.
PubMed

HADI Y, Kochhar GS
Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic-authors' reply.
Aliment Pharmacol Ther. 2022;56:178.
PubMed

LO SW, Garg M, Segal JP
Letter: normalising the ileoanal pouch-more than a one-step technique.
Aliment Pharmacol Ther. 2022;56:174-175.
PubMed

BHURWAL A, Mutneja H, Seril D
Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain. Authors' reply.
Aliment Pharmacol Ther. 2022;56:164-165.
PubMed

BENCHIMOL EI, Kuenzig ME
Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain.
Aliment Pharmacol Ther. 2022;56:162-163.
PubMed

HADI Y, Kochhar GS
Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2022;56:179.
PubMed

FEHILY SR, Al-Ani AH, Abdelmalak J, Rentch C, et al
Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.
Aliment Pharmacol Ther. 2022;56:6-27.
PubMed Abstract available

VAUGHAN R, Tjandra D, Patwardhan A, Mingos N, et al
Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease.
Aliment Pharmacol Ther. 2022;56:84-94.
PubMed Abstract available

LYONS M, Derikx LAAP, Fulforth J, McCall S, et al
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis.
Aliment Pharmacol Ther. 2022;56:67-76.
PubMed Abstract available

ROBLIN X, Veyrard P, Bastide L, Berger AE, et al
Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease.
Aliment Pharmacol Ther. 2022;56:77-83.
PubMed Abstract available

MASSIRONI S, Vigano C, Danese S
Letter: pancreatic involvement in inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2022;56:371.
PubMed

DAI C, Huang YH
Letter: pancreatic involvement in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022;56:370.
PubMed

SOLITANO V, Armuzzi A
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis-a step towards precision medicine?
Aliment Pharmacol Ther. 2022;56:347-348.
PubMed

FRIEDMAN S
Editorial: measuring fertility in men with inflammatory bowel disease.
Aliment Pharmacol Ther. 2022;56:345-346.
PubMed

GILL M, Majumdar A
Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game.
Aliment Pharmacol Ther. 2022;56:353-354.
PubMed

KO KL, Hung IF, Leung WK
Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game. Authors' reply.
Aliment Pharmacol Ther. 2022;56:355-356.
PubMed

MADSEN GR, Wilkens R, Boysen T, Burisch J, et al
The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases-an international Delphi consensus survey.
Aliment Pharmacol Ther. 2022;56:263-270.
PubMed Abstract available

PUGLIESE D, Privitera G, Crispino F, Mezzina N, et al
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
Aliment Pharmacol Ther. 2022;56:95-109.
PubMed Abstract available

June 2022

UMAR N, King D, Chandan JS, Bhala N, et al
The association between inflammatory bowel disease and mental ill health: A retrospective cohort study using data from UK primary care.
Aliment Pharmacol Ther. 2022 Jun 30. doi: 10.1111/apt.17110.
PubMed Abstract available

FRIEDMAN S, Garvik OS, Nielsen J, Norgard BM, et al
Paternal use of medications for inflammatory bowel disease and the risk of hospital-diagnosed infections in the offspring: A nationwide cohort study.
Aliment Pharmacol Ther. 2022 Jun 30. doi: 10.1111/apt.17113.
PubMed Abstract available

YUAN WQ, Li F, Yang LC, Yang ZL, et al
Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic.
Aliment Pharmacol Ther. 2022;55:1464-1465.
PubMed

WANG CY, Lai CC
Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2022;55:1462-1463.
PubMed

QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
Defining normal pouch function in patients with ileal pouch-anal anastomosis: a pilot study.
Aliment Pharmacol Ther. 2022;55:1560-1568.
PubMed Abstract available

HAWTHORNE AB, Glatter J, Blackwell J, Ainley R, et al
Inflammatory bowel disease patient-reported quality assessment should drive service improvement: A national survey of UK IBD units and patients.
Aliment Pharmacol Ther. 2022 Jun 1. doi: 10.1111/apt.17042.
PubMed Abstract available

May 2022

SWAMINATHAN A, Fan D, Borichevsky GM, Mules TC, et al
The disease severity index for inflammatory bowel disease is associated with psychological symptoms, quality of life and predicts a more complicated disease course.
Aliment Pharmacol Ther. 2022 May 27. doi: 10.1111/apt.17058.
PubMed Abstract available

ROSIOU K, Carbonell J, Dolby V, Monfared N, et al
Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study.
Aliment Pharmacol Ther. 2022 May 24. doi: 10.1111/apt.17039.
PubMed Abstract available

DRUVEFORS E, Andersson RE, Hammar U, Landerholm K, et al
Minor impact on fertility in men with inflammatory bowel disease: A National Cohort Study from Sweden.
Aliment Pharmacol Ther. 2022 May 22. doi: 10.1111/apt.16984.
PubMed Abstract available

KO KL, Lam YF, Cheung KS, Hung IF, et al
Clinical trial: intra-dermal hepatitis B vaccination with topical imiquimod versus intra-muscular hepatitis B vaccination in inflammatory bowel disease patients.
Aliment Pharmacol Ther. 2022 May 11. doi: 10.1111/apt.16970.
PubMed Abstract available

TAXONERA C, Fernandez-Acenero MJ, Olivares D, Calvo M, et al
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
Aliment Pharmacol Ther. 2022 May 4. doi: 10.1111/apt.16964.
PubMed Abstract available

MASSIRONI S, Fanetti I, Vigano C, Pirola L, et al
Systematic review-Pancreatic involvement in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 May 3. doi: 10.1111/apt.16949.
PubMed Abstract available

FALLOON K, Cohen B, Rieder F
Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2022;55:1208-1209.
PubMed

HADI Y, Kochhar GS
Letter: association between COVID-19 and inflammatory bowel disease-Authors' reply.
Aliment Pharmacol Ther. 2022;55:1228-1229.
PubMed

KOKKOTIS G, Kitsou K, Bamias G
Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
Aliment Pharmacol Ther. 2022;55:1235-1236.
PubMed

ARDALAN ZS, Friedman AB
Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment.
Aliment Pharmacol Ther. 2022;55:1202-1203.
PubMed

GUILLO L, Peyrin-Biroulet L, Danese S
Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022;55:1206-1207.
PubMed

BURISCH J, Langholz E, Munkholm P
Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' reply.
Aliment Pharmacol Ther. 2022;55:1239-1240.
PubMed

CHEN HY, Wang SI, Chang R, Wei JC, et al
Letter: association between COVID-19 and inflammatory bowel disease.
Aliment Pharmacol Ther. 2022;55:1226-1227.
PubMed

DEMARZO MG, Viola A, Picci A, Fries W, et al
Letter: the clinical course of Crohn's disease-the Sicilian experience.
Aliment Pharmacol Ther. 2022;55:1237-1238.
PubMed

SAGAMI S, Kobayashi T
Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment. Authors' reply.
Aliment Pharmacol Ther. 2022;55:1204-1205.
PubMed

BACHOUR SP, Shah RS, Lyu R, Rieder F, et al
Mild neoterminal ileal post-operative recurrence of Crohn's disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions.
Aliment Pharmacol Ther. 2022;55:1139-1150.
PubMed Abstract available

WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease.
Aliment Pharmacol Ther. 2022;55:1151-1159.
PubMed Abstract available

WANG J, Goren I, Rieder F
Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease. Authors' reply.
Aliment Pharmacol Ther. 2022;55:1360.
PubMed

FERNANDES RG, Radford-Smith G
Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?
Aliment Pharmacol Ther. 2022;55:1350-1351.
PubMed

RADEKE HH, Stein J
Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022;55:1359.
PubMed

OKABAYASHI S, Yamazaki H, Matsuoka K, Yamamoto Y, et al
Editorial: is older-onset ulcerative colitis more severe or less aggressively managed? Authors' reply.
Aliment Pharmacol Ther. 2022;55:1352-1353.
PubMed

KUMAR P, Vuyyuru SK, Kedia S, Ahuja V, et al
Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF-therapy-authors' reply.
Aliment Pharmacol Ther. 2022;55:1348-1349.
PubMed

LOVATT J, Selinger CP
Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF therapy.
Aliment Pharmacol Ther. 2022;55:1346-1347.
PubMed

April 2022

VERSTOCKT B, Volk V, Jaeckel C, Alsoud D, et al
Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
Aliment Pharmacol Ther. 2022 Apr 28. doi: 10.1111/apt.16955.
PubMed Abstract available

VANDE CASTEELE N, Sandborn WJ, Feagan BG, Vermeire S, et al
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
Aliment Pharmacol Ther. 2022 Apr 27. doi: 10.1111/apt.16937.
PubMed Abstract available

BERGQVIST V, Holmgren J, Klintman D, Marsal J, et al
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Apr 25. doi: 10.1111/apt.16927.
PubMed Abstract available

HALFVARSON JF, Ludvigsson JF, Bresso F, Askling J, et al
Age determines the risk of familial inflammatory bowel disease-A nationwide study.
Aliment Pharmacol Ther. 2022 Apr 22. doi: 10.1111/apt.16938.
PubMed Abstract available

MOENS A, Sadat Seyed Tabib N, Ballet V, Sabino J, et al
Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral Centre.
Aliment Pharmacol Ther. 2022 Apr 20. doi: 10.1111/apt.16928.
PubMed Abstract available

KHALILI H, Casey K
Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs-authors' reply.
Aliment Pharmacol Ther. 2022;55:884.
PubMed

YIN JQ, Wang BQ, Chen ZB, He HD, et al
Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs.
Aliment Pharmacol Ther. 2022;55:882-883.
PubMed

MUNGMUNPUNTIPANTIP R, Wiwanitkit V
Letter: inflammatory bowel disease services during the Covid-19 pandemic.
Aliment Pharmacol Ther. 2022;55:1063.
PubMed

DEPUTY M, Hart A, Faiz O
Letter: inflammatory bowel disease services during the Covid-19 pandemic - authors' reply.
Aliment Pharmacol Ther. 2022;55:1064.
PubMed

SELINGER CP, Lenti MV, De Silvestri A
Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.
Aliment Pharmacol Ther. 2022;55:1070-1071.
PubMed

ADOMI M, Ray A
Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease.
Aliment Pharmacol Ther. 2022;55:1069.
PubMed

KIM ES, Choi S, Choi SY, Park JH, et al
NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
Aliment Pharmacol Ther. 2022;55:1008-1015.
PubMed Abstract available

ALSOUD D, Verstockt B, Vermeire S
Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.
Aliment Pharmacol Ther. 2022;55:885-886.
PubMed

YANG H, Li B, Guo Q, Tang J, et al
Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.
Aliment Pharmacol Ther. 2022;55:764-777.
PubMed Abstract available

LENTI MV, Dolby V, Clark T, Hall V, et al
A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
Aliment Pharmacol Ther. 2022;55:856-866.
PubMed Abstract available

March 2022

BHURWAL A, Mutneja H, Bansal V, Goel A, et al
Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: A systematic review, meta-analysis and meta-regression.
Aliment Pharmacol Ther. 2022 Mar 30. doi: 10.1111/apt.16913.
PubMed Abstract available

TOWNSEND CM, Lovegrove F, Khanna R, Wilson AS, et al
Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Mar 21. doi: 10.1111/apt.16883.
PubMed Abstract available

ZAMANI M, Alizadeh-Tabari S, Singh S, Loomba R, et al
Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16879.
PubMed Abstract available

OKABAYASHI S, Yamazaki H, Tominaga K, Miura M, et al
Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: A multicentre cohort study.
Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16865.
PubMed Abstract available

FALLOON K, Cohen B, Ananthakrishnan AN, Barnes EL, et al
A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16853.
PubMed Abstract available

SINGH AK, Jena A, Mahajan G, Mohindra R, et al
Meta-analysis: Hepatitis B vaccination in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16880.
PubMed Abstract available

SUNG KY, Zhang B, Wang HE, Bai YM, et al
Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study.
Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16856.
PubMed Abstract available

PANACCIONE R, Abreu MT, Lazariciu I, Mundayat R, et al
Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open.
Aliment Pharmacol Ther. 2022 Mar 5. doi: 10.1111/apt.16848.
PubMed

JAYASOORIYA N, Blackwell J, Saxena S, Bottle A, et al
Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study.
Aliment Pharmacol Ther. 2022 Mar 4. doi: 10.1111/apt.16820.
PubMed Abstract available

SAVELKOUL EHJ, Hoentjen F
Editorial: anti-TNF combination therapy for inflammatory bowel disease-one size does not fit all.
Aliment Pharmacol Ther. 2022;55:750-751.
PubMed

HONAP S, Dart RJ, Samaan MA
Editorial: protecting hypoxia-inducible factor-1alpha and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis?
Aliment Pharmacol Ther. 2022;55:733-734.
PubMed

DANESE S, Levesque BG, Feagan BG, Jucov A, et al
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply.
Aliment Pharmacol Ther. 2022;55:735-736.
PubMed

KUMAR P, Vuyyuru SK, Kante B, Sahu P, et al
Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
Aliment Pharmacol Ther. 2022 Mar 1. doi: 10.1111/apt.16839.
PubMed Abstract available

ZHAO M, Sall Jensen M, Knudsen T, Kelsen J, et al
Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study.
Aliment Pharmacol Ther. 2022;55:541-557.
PubMed Abstract available

COLMAN RJ, Xiong Y, Mizuno T, Hyams JS, et al
Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease.
Aliment Pharmacol Ther. 2022;55:593-603.
PubMed Abstract available

COHEN NA, Pekow J
Editorial: time to modify practice and use the modified Rutgeert's score.
Aliment Pharmacol Ther. 2022;55:754-755.
PubMed

BANERJEE R, Raghunathan N
Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease?
Aliment Pharmacol Ther. 2022;55:740-741.
PubMed

KIM ES, Kang B
Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease? Authors' reply.
Aliment Pharmacol Ther. 2022;55:742-743.
PubMed

February 2022

BALLESTER MP, Mesonero F, Florez-Diez P, Gomez C, et al
Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study.
Aliment Pharmacol Ther. 2022 Feb 27. doi: 10.1111/apt.16832.
PubMed Abstract available

SAGAMI S, Kobayashi T, Aihara K, Umeda M, et al
Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis.
Aliment Pharmacol Ther. 2022 Feb 25. doi: 10.1111/apt.16817.
PubMed Abstract available

YE Z, Qian L, Hu W, Miao S, et al
Clinical outcome of infantile-onset inflammatory bowel disease in 102 patients with interleukin-10 signalling deficiency.
Aliment Pharmacol Ther. 2022 Feb 20. doi: 10.1111/apt.16837.
PubMed Abstract available

GROSSBERG LB, Papamichael K, Cheifetz AS
Review: emerging drug therapies in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16785.
PubMed Abstract available

WAN J, Wang X, Zhang Y, Chen M, et al
Systematic review and meta-analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and low-grade dysplasia.
Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16789.
PubMed Abstract available

DEPUTY M, Sahnan K, Worley G, Patel K, et al
The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study.
Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16800.
PubMed Abstract available

SCHREIBER S, Irving PM, Sharara AI, Martin-Arranz MD, et al
Review: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions.
Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16781.
PubMed Abstract available

POLLOK RCG, Jayasooriya N
Editorial: early and persistent biological treatment and its impact on long term surgical outcomes in inflammatory bowel disease.
Aliment Pharmacol Ther. 2022;55:370-371.
PubMed

TAXONERA C
Editorial: real-world safety of tofacitinib in ulcerative colitis.
Aliment Pharmacol Ther. 2022;55:368-369.
PubMed

MAHMOUD R, Schultheiss JPD, Fidder HH, Oldenburg B, et al
Letter: loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2022;55:499-500.
PubMed

BEN-HORIN S, Ungar B
Letter: loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease depends on treatment duration.
Aliment Pharmacol Ther. 2022;55:497-498.
PubMed

GOODSALL TM, Bryant RV
Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US.
Aliment Pharmacol Ther. 2022;55:360-361.
PubMed

ALLOCCA M, Danese S
Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US. Authors' reply.
Aliment Pharmacol Ther. 2022;55:362-363.
PubMed

ALLOCCA M, Craviotto V, Dell'Avalle C, Furfaro F, et al
Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease.
Aliment Pharmacol Ther. 2022;55:446-454.
PubMed Abstract available

SKEJO C, Vestergaard T, Julsgaard M
Editorial: safety of ustekinumab in pregnancy-are we there yet?
Aliment Pharmacol Ther. 2022;55:495-496.
PubMed

CARON B, Fumery M, Netter P, Peyrin-Biroulet L, et al
Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure.
Aliment Pharmacol Ther. 2022;55:508-509.
PubMed

PARROT L, Dong C, Carbonnel F, Meyer A, et al
Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
Aliment Pharmacol Ther. 2022;55:380-388.
PubMed Abstract available

January 2022

THOMSEN SB, Ungaro RC, Allin KH, Elmahdi R, et al
Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
Aliment Pharmacol Ther. 2022 Jan 25. doi: 10.1111/apt.16777.
PubMed Abstract available

DANESE S, Levesque BG, Feagan BG, Jucov A, et al
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1alpha stabiliser, for treatment of ulcerative colitis.
Aliment Pharmacol Ther. 2022 Jan 10. doi: 10.1111/apt.16753.
PubMed Abstract available

VEISMAN I, Ben-Horin S
Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients.
Aliment Pharmacol Ther. 2022;55:131-132.
PubMed

LAHARIE D, Riviere P
Editorial: don't forget basic performance measures in the endoscopic assessment of ulcerative colitis.
Aliment Pharmacol Ther. 2022;55:129-130.
PubMed

CARBONNEL F, Meyer A
Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences.
Aliment Pharmacol Ther. 2022;55:251-252.
PubMed

GOREN I, Yanai H
Editorial: risk of loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease-the longer the less?
Aliment Pharmacol Ther. 2022;55:244-245.
PubMed

HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences. Authors' reply.
Aliment Pharmacol Ther. 2022;55:253-254.
PubMed

VASUDEVAN A, van Langenberg DR
Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy.
Aliment Pharmacol Ther. 2022;55:108-109.
PubMed

BURISCH J, Langholz E, Munkholm P
Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy-authors' reply.
Aliment Pharmacol Ther. 2022;55:110-111.
PubMed

KHAN N, Patel D, Trivedi C, Pernes T, et al
The impact of IBD medications on risk of pneumonia and pneumonia-related hospitalisation: a nationwide cohort study of 56 410 IBD patients.
Aliment Pharmacol Ther. 2022;55:64-72.
PubMed Abstract available

BURISCH J, Lophaven S, Langholz E, Munkholm P, et al
The clinical course of Crohn's disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962-2017.
Aliment Pharmacol Ther. 2022;55:73-82.
PubMed Abstract available

REZAZADEH ARDABILI A, Mujagic Z, Jonkers DMAE, Pierik MJ, et al
Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring.
Aliment Pharmacol Ther. 2022;55:260-261.
PubMed

SCHULTHEISS JPD, Mahmoud R, Fidder HH, Oldenburg B, et al
Editorial: risk of loss of response to anti TNFalpha in patients with inflammatory bowel diseases - the longer the less? Authors' reply.
Aliment Pharmacol Ther. 2022;55:246.
PubMed

KHAN N, Yang YX
Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring. Authors' reply.
Aliment Pharmacol Ther. 2022;55:262.
PubMed

MA C, MacDonald JK, Nguyen TM, Chang J, et al
Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis.
Aliment Pharmacol Ther. 2022;55:178-190.
PubMed Abstract available

December 2021

WANG J, Goren I, Yang B, Lin S, et al
The sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis: a unique therapeutic target in inflammatory bowel disease.
Aliment Pharmacol Ther. 2021 Dec 21. doi: 10.1111/apt.16741.
PubMed Abstract available

FLANAGAN E, Prentice R, Wright EK, Gibson PR, et al
Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero.
Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16739.
PubMed Abstract available

FORSS A, Clements M, Bergman D, Roelstraete B, et al
A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014.
Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16735.
PubMed Abstract available

HADI Y, Dulai PS, Kupec J, Mohy-Ud-Din N, et al
Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis.
Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16730.
PubMed Abstract available

CASEY K, Lopes EW, Niccum B, Burke K, et al
Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts.
Aliment Pharmacol Ther. 2021 Dec 8. doi: 10.1111/apt.16731.
PubMed Abstract available

MESERVE J, Singh S
Editorial: risk of pneumonia in IBD-reading between the lines!
Aliment Pharmacol Ther. 2021;54.
PubMed

HAMDEH S, Micic D, Hanauer S
Review article: drug-induced small bowel injury.
Aliment Pharmacol Ther. 2021;54.
PubMed Abstract available

SANDBORN WJ, Lawendy N, Danese S, Su C, et al
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
Aliment Pharmacol Ther. 2021 Dec 1. doi: 10.1111/apt.16712.
PubMed Abstract available

November 2021

ZHAO M, Feng R, Ben-Horin S, Zhuang X, et al
Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations.
Aliment Pharmacol Ther. 2021 Nov 24. doi: 10.1111/apt.16703.
PubMed Abstract available

RADHAKRISHNAN ST, Alexander JL, Mullish BH, Gallagher KI, et al
Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
Aliment Pharmacol Ther. 2021 Nov 9. doi: 10.1111/apt.16656.
PubMed Abstract available

CHAO K, Huang Y, Zhu X, Tang J, et al
Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.
Aliment Pharmacol Ther. 2021;54:1124-1133.
PubMed Abstract available

October 2021

BURISCH J, Lophaven S, Munkholm P, Langholz E, et al
Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962-1987 and followed until 2017 in a Danish population-based inception cohort.
Aliment Pharmacol Ther. 2021 Oct 29. doi: 10.1111/apt.16677.
PubMed Abstract available

BEZZIO C, Armuzzi A, Furfaro F, Ardizzone S, et al
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Aliment Pharmacol Ther. 2021 Oct 25. doi: 10.1111/apt.16663.
PubMed Abstract available

PASVOL TJ, Bloom S, Segal AW, Rait G, et al
Use of contraceptives and risk of inflammatory bowel disease: A nested case-control study.
Aliment Pharmacol Ther. 2021 Oct 18. doi: 10.1111/apt.16647.
PubMed Abstract available

RUBIN DT, Modesto I, Vermeire S, Danese S, et al
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.
Aliment Pharmacol Ther. 2021 Oct 9. doi: 10.1111/apt.16619.
PubMed Abstract available

FEAGAN BG, Khanna R, Sandborn WJ, Vermeire S, et al
Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
Aliment Pharmacol Ther. 2021 Oct 6. doi: 10.1111/apt.16626.
PubMed Abstract available

TAKENAKA K, Kawamoto A, Ohtsuka K
Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease-authors' reply.
Aliment Pharmacol Ther. 2021;54:1087.
PubMed

RAKOWSKY S, Cheifetz AS, Papamichael K
Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
Aliment Pharmacol Ther. 2021;54:1085-1086.
PubMed

JOLVING LR, Anru PL, Nielsen J, Friedman S, et al
The risk of chronic diseases and congenital malformations during childhood and adolescence after in utero exposure to thiopurines.
Aliment Pharmacol Ther. 2021;54:1061-1069.
PubMed Abstract available

SAINZ E, Zabana Y, Miguel I, Fernandez-Clotet A, et al
Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study).
Aliment Pharmacol Ther. 2021;54:1041-1051.
PubMed Abstract available

TAKENAKA K, Kawamoto A, Hibiya S, Suzuki K, et al
Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
Aliment Pharmacol Ther. 2021;54:1052-1060.
PubMed Abstract available

September 2021

MULES TC, Swaminathan A, Hirschfeld E, Borichevsky G, et al
The impact of disease activity on psychological symptoms and quality of life in patients with inflammatory bowel disease-results from the Stress, Anxiety and Depression with Disease Activity (SADD) Study.
Aliment Pharmacol Ther. 2021 Sep 29. doi: 10.1111/apt.16616.
PubMed Abstract available

SCHULTHEISS JPD, Mahmoud R, Louwers JM, van der Kaaij MT, et al
Loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16605.
PubMed Abstract available

HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis.
Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16609.
PubMed Abstract available

DOHERTY J, Fennessy S, Stack R, O' Morain N, et al
Review Article: Vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
Aliment Pharmacol Ther. 2021 Sep 2. doi: 10.1111/apt.16590.
PubMed Abstract available

SAITTA D, Garg M
Letter: missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease-still significant room for improvement.
Aliment Pharmacol Ther. 2021;54:734-735.
PubMed

BLESL A, Hogenauer C, Borenich A, Berghold A, et al
Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.
Aliment Pharmacol Ther. 2021;54:720-721.
PubMed

BLESL A, Binder L, Hogenauer C, Wenzl H, et al
Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.
Aliment Pharmacol Ther. 2021;54:667-677.
PubMed Abstract available

VISURI I, Eriksson C, Olen O, Cao Y, et al
Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
Aliment Pharmacol Ther. 2021;54:848-849.
PubMed

VEYRARD P, Nancey S, Roblin X
Editorial: 5-ASA in IBD patients on biologics-'stop or continue'?
Aliment Pharmacol Ther. 2021;54:843-844.
PubMed

BERNSTEIN CN, Tennakoon A, Singh H, Targownik L, et al
Editorial: 5-ASA in IBD patients on biologics-'stop or continue'? Authors' reply.
Aliment Pharmacol Ther. 2021;54:845.
PubMed

HAYDEK JP, Scott FI
Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence.
Aliment Pharmacol Ther. 2021;54:846-847.
PubMed

PIERRE N, Salee C, Vieujean S, Bequet E, et al
Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology.
Aliment Pharmacol Ther. 2021;54:779-791.
PubMed Abstract available

BERNSTEIN CN, Tenakoon A, Singh H, Targownik LE, et al
Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study.
Aliment Pharmacol Ther. 2021;54:814-832.
PubMed Abstract available

August 2021

SLEUTJES JAM, Roeters van Lennep JE, Boersma E, Menchen LA, et al
Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels.
Aliment Pharmacol Ther. 2021 Aug 28. doi: 10.1111/apt.16580.
PubMed Abstract available

HONAP S, Pavlidis P, Irving PM
Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?
Aliment Pharmacol Ther. 2021;54:341-342.
PubMed

BIEMANS VBC, Straatmijer T, Hoentjen F, Pierik MJ, et al
Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.
Aliment Pharmacol Ther. 2021;54:534-535.
PubMed

LO SW, Connell W, Kamm MA, Lust M, et al
Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia.
Aliment Pharmacol Ther. 2021;54:532-533.
PubMed

ROBLIN X, Nancey S, Paul S
Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply.
Aliment Pharmacol Ther. 2021;54:538-539.
PubMed

FRIEDMAN AB, Gibson PR
Editorial: assessment of inflammatory bowel disease: a picture is worth a thousand words. Authors' reply.
Aliment Pharmacol Ther. 2021;54:510.
PubMed

HORJUS-TALABUR HORJE CS, van Bodegraven AA
Editorial: assessment of inflammatory bowel disease-a picture is worth a thousand words.
Aliment Pharmacol Ther. 2021;54:508-509.
PubMed

TSOI AH, Murugasu A, Garg M
Letter: assessment of histological disease activity in Crohn's disease clinical trials-a step in the right direction, but further optimisation needed.
Aliment Pharmacol Ther. 2021;54:541-542.
PubMed

DEMARZO MG, Bodini G, Giuliana E, Zentilin P, et al
Letter: predictive factors for treatment discontinuation in IBD-anti-TNF trough levels and anti-drug antibodies.
Aliment Pharmacol Ther. 2021;54:536-537.
PubMed

MATTOO VY, Basnayake C, Connell WR, Ding N, et al
Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease.
Aliment Pharmacol Ther. 2021;54:249-266.
PubMed Abstract available

July 2021

LAMBERT K, Pappas D, Miglioretto C, Javadpour A, et al
Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease.
Aliment Pharmacol Ther. 2021 Jul 29. doi: 10.1111/apt.16549.
PubMed Abstract available

FUMERY M, Filippi J, Abitbol V, Biron A, et al
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
Aliment Pharmacol Ther. 2021 Jul 23. doi: 10.1111/apt.16544.
PubMed Abstract available

VISURI I, Eriksson C, Olen O, Cao Y, et al
Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.
Aliment Pharmacol Ther. 2021 Jul 19. doi: 10.1111/apt.16525.
PubMed Abstract available

MCGING JJ, Radford SJ, Francis ST, Serres S, et al
Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies.
Aliment Pharmacol Ther. 2021 Jul 6. doi: 10.1111/apt.16465.
PubMed Abstract available

LUBER RP, O'Neill R, Singh S, Sharma E, et al
An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
Aliment Pharmacol Ther. 2021 Jul 5. doi: 10.1111/apt.16497.
PubMed Abstract available

ROTONDO-TRIVETTE S, Wang B, Gayer C, Parsana R, et al
Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection.
Aliment Pharmacol Ther. 2021 Jul 4. doi: 10.1111/apt.16496.
PubMed Abstract available

OSENI E, Sultan K
Letter: opioid use, early biologic discontinuation for inflammatory bowel disease and a cautionary note for the age of legalised cannabis.
Aliment Pharmacol Ther. 2021;54:92-93.
PubMed

JORDI SBU, Misselwitz B, Begre S
Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2021;54:82-83.
PubMed

KNOWLES SR, Mikocka-Walus A
Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease.
Aliment Pharmacol Ther. 2021;54:80-81.
PubMed

FAN D, Gearry RB
Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?
Aliment Pharmacol Ther. 2021;54:208-209.
PubMed

TASSONE D, Singh S, Sheng Ding N
Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib.
Aliment Pharmacol Ther. 2021;54:206-207.
PubMed

MEYER A, Semenzato L, Zureik M, Weill A, et al
Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
Aliment Pharmacol Ther. 2021;54:160-166.
PubMed Abstract available

CASANOVA MJ, Chaparro M, Gisbert JP
Editorial: withdrawal of anti-TNFalpha-are we ready for biological therapy cycling? Authors' reply.
Aliment Pharmacol Ther. 2021;54:86-87.
PubMed

PUGLIESE D, Armuzzi A
Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling?
Aliment Pharmacol Ther. 2021;54:84-85.
PubMed

WEISSHOF R, Chowers Y, Kurnik D
Editorial: safety of thiopurines in pregnancy-considering the mother, foetus and newborn.
Aliment Pharmacol Ther. 2021;54:88-89.
PubMed

June 2021

FARRAYE FA, Qazi T, Kotze PG, Moore GT, et al
The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
Aliment Pharmacol Ther. 2021 Jun 24. doi: 10.1111/apt.16439.
PubMed Abstract available

MEYER A, Drouin J, Weill A, Carbonnel F, et al
Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
Aliment Pharmacol Ther. 2021 Jun 23. doi: 10.1111/apt.16448.
PubMed Abstract available

FRIEDMAN AB, Asthana A, Knowles SR, Robbins A, et al
Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease.
Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16452.
PubMed Abstract available

BERNSTEIN CN, Nugent Z, Shaffer S, Singh H, et al
Comorbidity before and after a diagnosis of inflammatory bowel disease.
Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16444.
PubMed Abstract available

UZZAN M, Bresteau C, Laharie D, Stefanescu C, et al
Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16463.
PubMed Abstract available

KO Y, Paramsothy S, Yau Y, Leong RW, et al
Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16436.
PubMed Abstract available

VAN LINSCHOTEN RCA, Visser E, Niehot CD, van der Woude CJ, et al
Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.
Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16445.
PubMed Abstract available

FAIRBRASS KM, Gracie DJ, Ford AC
Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.
Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16454.
PubMed Abstract available

LAMB CA, Sebastian S, Kent AJ, Segal JP, et al
Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
Aliment Pharmacol Ther. 2021;53:1236-1240.
PubMed

EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
Editorial: trends in paediatric inflammatory bowel disease attributable direct costs-authors' reply.
Aliment Pharmacol Ther. 2021;53:1234-1235.
PubMed

VERNON-ROBERTS A, Day AS
Editorial: trends in paediatric inflammatory bowel disease attributable direct costs.
Aliment Pharmacol Ther. 2021;53:1232-1233.
PubMed

TANNOURY J, Amiot A
Editorial: determining disability in inflammatory bowel disease-"See(k) and you shall find". Authors' reply.
Aliment Pharmacol Ther. 2021;53:1323.
PubMed

TURBAYNE AKB, Ward MG
Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind.
Aliment Pharmacol Ther. 2021;53:1317-1318.
PubMed

ROBLIN X, Nancey S, Paul S
Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply.
Aliment Pharmacol Ther. 2021;53:1319-1320.
PubMed

LIMDI JK
Editorial: determining disability in IBD - 'See(k) and you shall find'.
Aliment Pharmacol Ther. 2021;53:1321-1322.
PubMed

MANLAY L, Boschetti G, Pereira B, Flourie B, et al
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
Aliment Pharmacol Ther. 2021;53:1289-1299.
PubMed Abstract available

May 2021

JORDI SBU, Botte F, Lang BM, Greuter T, et al
Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease.
Aliment Pharmacol Ther. 2021 May 11. doi: 10.1111/apt.16365.
PubMed Abstract available

CASANOVA MJ, Chaparro M, Nantes O, Benitez JM, et al
Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
Aliment Pharmacol Ther. 2021 May 7. doi: 10.1111/apt.16361.
PubMed Abstract available

SRINIVASAN A, Haifer C, Thin L
Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD.
Aliment Pharmacol Ther. 2021;53:1038-1039.
PubMed

WILSON A, Kim RB
Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-alpha antagonist immunogenicity - does location matter?
Aliment Pharmacol Ther. 2021;53:1055-1056.
PubMed

DEMARZO MG, Bodini G, Vanello M, Martini M, et al
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.
Aliment Pharmacol Ther. 2021;53:1044-1045.
PubMed

RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.
Aliment Pharmacol Ther. 2021;53:1046-1047.
PubMed

MESONERO F, Castro-Poceiro J, Benitez JM, Camps B, et al
Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-alpha: results from the ENEIDA registry.
Aliment Pharmacol Ther. 2021;53:1021-1029.
PubMed Abstract available

SEDANO R, Ma C, Jairath V
Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction. Authors' reply.
Aliment Pharmacol Ther. 2021;53:1149-1150.
PubMed

LAUBE R, Selinger CP
Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction.
Aliment Pharmacol Ther. 2021;53:1147-1148.
PubMed

TANNOURY J, Nachury M, Martins C, Serrero M, et al
Determinants of IBD-related disability: a cross-sectional survey from the GETAID.
Aliment Pharmacol Ther. 2021;53:1098-1107.
PubMed Abstract available

TJANDRA D, Garg M, Behrenbruch C, McCormick J, et al
Review article: investigation and management of internal fistulae in Crohn's disease.
Aliment Pharmacol Ther. 2021;53:1064-1079.
PubMed Abstract available

April 2021

DHALIWAL J, McKay HE, Deslandres C, Debruyn J, et al
One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
Aliment Pharmacol Ther. 2021 Apr 28. doi: 10.1111/apt.16388.
PubMed Abstract available

TOURNIER Q, Paul S, Williet N, Berger AE, et al
Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
Aliment Pharmacol Ther. 2021 Apr 19. doi: 10.1111/apt.16333.
PubMed Abstract available

EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
Trends in paediatric inflammatory bowel disease-attributable direct costs: a population-based analysis.
Aliment Pharmacol Ther. 2021 Apr 9. doi: 10.1111/apt.16358.
PubMed Abstract available

VAN DER HAVE M, Maljaars J
Editorial: opioids in inflammatory bowel disease-primum non nocere.
Aliment Pharmacol Ther. 2021;53:844-845.
PubMed

RHUDY C, Perry CL, Barrett TA
Editorial: opioids in inflammatory bowel disease-primum non nocere. Authors' reply.
Aliment Pharmacol Ther. 2021;53:846.
PubMed

JANGI S, Yoon H, Dulai P, Valasek M, et al
Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply.
Aliment Pharmacol Ther. 2021;53:957-958.
PubMed

MAEDA Y, Kudo SE, Takishima K, Misawa M, et al
Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis.
Aliment Pharmacol Ther. 2021;53:955-956.
PubMed

PRENTICE RE, Hollingsworth L, Middleton C, Wilson J, et al
Letter: colorectal cancer surveillance in inflammatory bowel disease-a call for systematic reform.
Aliment Pharmacol Ther. 2021;53:953-954.
PubMed

LUBELL JM
Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes.
Aliment Pharmacol Ther. 2021;53:851-852.
PubMed

BAGER P, Hvas C, Rud C, Dahlerup J, et al
Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes. Authors' reply.
Aliment Pharmacol Ther. 2021;53:853-854.
PubMed

LIM G, Kassam Z, Seow CH
Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity?
Aliment Pharmacol Ther. 2021;53:855-856.
PubMed

TURSI A, Mocci G, Picchio M, Elisei W, et al
Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.
Aliment Pharmacol Ther. 2021;53:859-860.
PubMed

LAHARIE D, Riviere P
Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity? Authors' reply.
Aliment Pharmacol Ther. 2021;53:857-858.
PubMed

ALMRADI A, Ma C, D'Haens GR, Sandborn WJ, et al
An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials.
Aliment Pharmacol Ther. 2021;53:784-793.
PubMed Abstract available

ABUSHAMMA S, Deepak P
Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials-is it ready for prime time yet?
Aliment Pharmacol Ther. 2021;53:946-947.
PubMed

JAIRATH V, Almradi A, Pai RK, Ma C, et al
Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials-a missing link. Authors' reply.
Aliment Pharmacol Ther. 2021;53:952.
PubMed

TANDON P, Narula N
Editorial: methotrexate in patients with Crohn's disease refractory to anti-TNF therapy-moving backwards yet forward?
Aliment Pharmacol Ther. 2021;53:950-951.
PubMed

GOODSALL TM, Jairath V, Bryant RV, Ma C, et al
Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials - is it ready for prime time yet? Authors' reply.
Aliment Pharmacol Ther. 2021;53:948-949.
PubMed

GOODSALL TM, Jairath V, Feagan BG, Parker CE, et al
Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease.
Aliment Pharmacol Ther. 2021;53:873-886.
PubMed Abstract available

March 2021

WORLEY G, Faiz O
Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages? Authors' reply.
Aliment Pharmacol Ther. 2021;53:661-662.
PubMed

BODGER K
Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages?
Aliment Pharmacol Ther. 2021;53:660.
PubMed

LAHARIE D
Editorial: is enteral nutrition back in acute severe ulcerative colitis?
Aliment Pharmacol Ther. 2021;53:745-746.
PubMed

AL-ANI AH, Prentice RE, Rentsch C, Christensen B, et al
Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.
Aliment Pharmacol Ther. 2021;53:766-767.
PubMed

SAHU P, Kedia S, Kumar Vuyyuru S, Travis S, et al
Editorial: is enteral nutrition back in acute severe ulcerative colitis? Authors' reply.
Aliment Pharmacol Ther. 2021;53:747-748.
PubMed

O'MORAIN N, Coe C, Mallon P, Twomey P, et al
Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active?
Aliment Pharmacol Ther. 2021;53:674-675.
PubMed

PRIVITERA G, Pugliese D, Scaldaferri F, Armuzzi A, et al
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.
Aliment Pharmacol Ther. 2021;53:764-765.
PubMed

TRYSTRAM N, Abitbol V, Tannoury J, Lecomte M, et al
Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16312.
PubMed Abstract available

KANESHIRO M, Takenaka K, Suzuki K, Fujii T, et al
Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission.
Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16310.
PubMed Abstract available

MANTZARIS GJ, Bamias G
Editorial: an expert consensus to standardise the assessment of histologic disease activity in Crohn's disease clinical trials-a missing link.
Aliment Pharmacol Ther. 2021;53:749-750.
PubMed

ROBLIN X, Paul S, Nancey S
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game.
Aliment Pharmacol Ther. 2021;53:640-641.
PubMed

RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.
Aliment Pharmacol Ther. 2021;53:642-643.
PubMed

MCCURDY J, Boet S, Rosenfeld G
Editorial: is hyperbaric oxygen a therapeutic opportunity for refractory perianal Crohn's disease?
Aliment Pharmacol Ther. 2021;53:667-668.
PubMed

LAFEUILLE P, Hordonneau C, Vignette J, Blayac L, et al
Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease.
Aliment Pharmacol Ther. 2021;53:577-586.
PubMed Abstract available

LANSDORP CA, Gecse KB, Buskens CJ, Lowenberg M, et al
Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease.
Aliment Pharmacol Ther. 2021;53:587-597.
PubMed Abstract available

February 2021

FLANAGAN E, Wright EK, Hardikar W, Sparrow MP, et al
Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates.
Aliment Pharmacol Ther. 2021 Feb 19. doi: 10.1111/apt.16294.
PubMed Abstract available

JAHRAUS CD
Editorial: "Please Sir, I want some more" data to guide delivery of abdominopelvic radiotherapy in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2021;53:454-455.
PubMed

AXELRAD JE
Editorial: immune-mediated diseases-are we closer to disease-defining molecular signatures?
Aliment Pharmacol Ther. 2021;53:563-564.
PubMed

DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.
Aliment Pharmacol Ther. 2021;53:445-446.
PubMed

WILS P, Pariente B
Editorial: keep calm and carry on-managing non-TNF antagonist biologics in pregnancy-authors' reply.
Aliment Pharmacol Ther. 2021;53:452-453.
PubMed

SEOW CH, Ma C
Keep calm and carry on-managing non-TNF antagonist biologics in pregnancy.
Aliment Pharmacol Ther. 2021;53:450-451.
PubMed

TOWNSEND T, Subramanian S
Editorial: vedolizumab in inflammatory bowel diseases-less is more?
Aliment Pharmacol Ther. 2021;53:443-444.
PubMed

MESERVE J, Facciorusso A, Holmer AK, Annese V, et al
Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
Aliment Pharmacol Ther. 2021;53:374-382.
PubMed Abstract available

January 2021

RHUDY C, Perry CL, Singleton M, Talbert J, et al
Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease.
Aliment Pharmacol Ther. 2021 Jan 26. doi: 10.1111/apt.16269.
PubMed Abstract available

SAHU P, Kedia S, Vuyyuru SK, Bajaj A, et al
Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis.
Aliment Pharmacol Ther. 2021 Jan 13. doi: 10.1111/apt.16249.
PubMed Abstract available

CHEE D, Kennedy NA, Goodhand JR, Ahmad T, et al
Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root. Authors' reply.
Aliment Pharmacol Ther. 2021;53:337-338.
PubMed

MAHMOUD R, Itzkowitz SH
Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root.
Aliment Pharmacol Ther. 2021;53:335-336.
PubMed

LORD A, Radford-Smith G
Letter: hidden costs in healthcare use for incident and prevalent Crohn's disease and ulcerative colitis.
Aliment Pharmacol Ther. 2021;53:368-369.
PubMed

RIMOLA J, Panes J, Ordas I
Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease-authors' reply.
Aliment Pharmacol Ther. 2021;53:207-208.
PubMed

DEBNATH P, Rathi P
Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease.
Aliment Pharmacol Ther. 2021;53:205-206.
PubMed

MURRAY CD
Editorial: fatigue-difficult to assess and difficult to treat.
Aliment Pharmacol Ther. 2021;53:339.
PubMed

LEBLANC JF, Hart AL
Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD.
Aliment Pharmacol Ther. 2021;53:342-343.
PubMed

TOWNSEND T, Subramanian S
Letter: propensity score-handle with care. Authors' reply.
Aliment Pharmacol Ther. 2021;53:362-363.
PubMed

MACALUSO FS, Orlando A
Letter: propensity score-handle with care.
Aliment Pharmacol Ther. 2021;53:360-361.
PubMed

CARBERY I, Selinger CP
Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD?
Aliment Pharmacol Ther. 2021;53:346-347.
PubMed

BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD. Authors' reply.
Aliment Pharmacol Ther. 2021;53:344-345.
PubMed

SCHREINER P, von Kanel R, Misselwitz B
Editorial: fatigue-difficult to assess and difficult to treat. Authors' reply.
Aliment Pharmacol Ther. 2021;53:340-341.
PubMed

BERTANI L, Pugliese D, Trico D, Costa F, et al
Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply.
Aliment Pharmacol Ther. 2021;53:348-349.
PubMed

NICE R, Chanchlani N, Green H, Bewshea C, et al
Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays.
Aliment Pharmacol Ther. 2021;53:128-137.
PubMed Abstract available

DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
Aliment Pharmacol Ther. 2021;53:265-272.
PubMed Abstract available

BERTANI L, Trico D, Pugliese D, Privitera G, et al
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients.
Aliment Pharmacol Ther. 2021;53:273-280.
PubMed Abstract available

FRAZZONI L, La Marca M, Radaelli F, Spada C, et al
Systematic review with meta-analysis: the appropriateness of colonoscopy increases the probability of relevant findings and cancer while reducing unnecessary exams.
Aliment Pharmacol Ther. 2021;53:22-32.
PubMed Abstract available

PAI RK, Pai RK, Brown I, Choi WT, et al
The significance of histological activity measurements in immune checkpoint inhibitor colitis.
Aliment Pharmacol Ther. 2021;53:150-159.
PubMed Abstract available

UNGARO RC, Hu L, Ji J, Nayar S, et al
Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease.
Aliment Pharmacol Ther. 2021;53:281-290.
PubMed Abstract available

KING D, Coupland B, Dosanjh A, Cole A, et al
The risk of later surgery at the anastomotic site following right hemicolectomy for Crohn's disease in a national cohort of 12 230 patients.
Aliment Pharmacol Ther. 2021;53:114-127.
PubMed Abstract available

December 2020

RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
Aliment Pharmacol Ther. 2020 Dec 19. doi: 10.1111/apt.16193.
PubMed Abstract available

YE L, Chapman TP, Wen Z, Lin L, et al
Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region.
Aliment Pharmacol Ther. 2020 Dec 12. doi: 10.1111/apt.16130.
PubMed Abstract available

PIOVANI D, Pansieri C, Peyrin-Biroulet L, Danese S, et al
Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study.
Aliment Pharmacol Ther. 2020 Dec 9. doi: 10.1111/apt.16222.
PubMed Abstract available

WILS P, Seksik P, Stefanescu C, Nancey S, et al
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
Aliment Pharmacol Ther. 2020 Dec 7. doi: 10.1111/apt.16192.
PubMed Abstract available

LO CH, Khalili H, Lochhead P, Song M, et al
Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study.
Aliment Pharmacol Ther. 2020 Dec 5. doi: 10.1111/apt.16210.
PubMed Abstract available

WORLEY G, Almoudaris A, Bassett P, Segal J, et al
Colectomy rates for ulcerative colitis in England 2003-2016.
Aliment Pharmacol Ther. 2020 Dec 2. doi: 10.1111/apt.16202.
PubMed Abstract available

REUKEN PA, Wust M, Loffler B, Bauer M, et al
Letter: SARS-CoV-2-induced gastrointestinal inflammation.
Aliment Pharmacol Ther. 2020;52.
PubMed

November 2020

DOHOS D, Hanak L, Szakacs Z, Kiss S, et al
Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease.
Aliment Pharmacol Ther. 2020 Nov 28. doi: 10.1111/apt.16182.
PubMed Abstract available

BROUSSARD D, Riviere P, Bonnet J, Fotsing G, et al
Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID.
Aliment Pharmacol Ther. 2020 Nov 26. doi: 10.1111/apt.16176.
PubMed Abstract available

BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease.
Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16166.
PubMed Abstract available

HIBIYA S, Matsuyama Y, Fujii T, Maeyashiki C, et al
5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis.
Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16120.
PubMed Abstract available

SCHREINER P, Rossel JB, Biedermann L, Valko PO, et al
Fatigue in inflammatory bowel disease and its impact on daily activities.
Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16145.
PubMed Abstract available

GORDON C, Chee D, Hamilton B, Heerasing NM, et al
Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16155.
PubMed Abstract available

MEYER A, Drouin J, Weill A, Carbonnel F, et al
Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018.
Aliment Pharmacol Ther. 2020;52:1480-1490.
PubMed Abstract available

NICOLAIDES S, Vasudevan A, van Langenberg D
Letter: rationalising aminosalicylates in inflammatory bowel disease.
Aliment Pharmacol Ther. 2020;52:1619-1620.
PubMed

MA C, Singh S, Heatherington J, Panaccione R, et al
Editorial: is age just a number when it comes to treatment of inflammatory bowel disease?
Aliment Pharmacol Ther. 2020;52:1615-1616.
PubMed

ASSCHER VER, Biemans VBC, Hoentjen F, Maljaars PWJ, et al
Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply.
Aliment Pharmacol Ther. 2020;52:1617-1618.
PubMed

CHAPMAN TP, Frias Gomes C, Louis E, Colombel JF, et al
Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2020;52:1621.
PubMed

NARULA N, Aruljothy A, Alshahrani AA, Fadida M, et al
Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission.
Aliment Pharmacol Ther. 2020 Nov 1. doi: 10.1111/apt.16147.
PubMed Abstract available

VASUDEVAN A, Con D, Nicolaides S, van Langenberg DR, et al
Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors' reply.
Aliment Pharmacol Ther. 2020;52:1529-1530.
PubMed

ZULFIQAR M, Deepak P
Editorial: crystal gazing with magnetic resonance enterography to predict the response to TNF-alpha inhibitors in Crohn's disease.
Aliment Pharmacol Ther. 2020;52:1531-1532.
PubMed

FRASER AG
Methotrexate or azathioprine-do differing rates of discontinuation settle the debate?
Aliment Pharmacol Ther. 2020;52:1527-1528.
PubMed

FLANAGAN E, Gibson PR, Wright EK, Moore GT, et al
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
Aliment Pharmacol Ther. 2020;52:1551-1562.
PubMed Abstract available

TAYLOR H, Serrano-Contreras JI, McDonald JAK, Epstein J, et al
Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease.
Aliment Pharmacol Ther. 2020;52:1491-1502.
PubMed Abstract available

RIMOLA J, Fernandez-Clotet A, Capozzi N, Rojas-Farreras S, et al
Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.
Aliment Pharmacol Ther. 2020;52:1563-1573.
PubMed Abstract available

October 2020

BANERJEE R, Ravikanth VV, Pal P, Bale G, et al
NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.
Aliment Pharmacol Ther. 2020 Oct 27. doi: 10.1111/apt.16137.
PubMed Abstract available

PANACCIONE R, Danese S, Sandborn WJ, O'Brien CD, et al
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
Aliment Pharmacol Ther. 2020 Oct 21. doi: 10.1111/apt.16119.
PubMed Abstract available

AMIOT A, Salameh R
Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy-authors' reply.
Aliment Pharmacol Ther. 2020;52:1252.
PubMed

FABIAN A, Bor R, Farkas K, Szepes Z, et al
Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy.
Aliment Pharmacol Ther. 2020;52:1251.
PubMed

PRENTICE RE, Tjandra D, Garg M, Lubel JS, et al
Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.
Aliment Pharmacol Ther. 2020;52:1422-1423.
PubMed

BRITTON E, Richardson P, Mian I, Conley T, et al
Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when?
Aliment Pharmacol Ther. 2020;52:1414-1415.
PubMed

BIEMANS VBC, Hoentjen F, Pierik MJ
Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
Aliment Pharmacol Ther. 2020;52:1255-1256.
PubMed

LIU K, Cai F, Huang J
Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
Aliment Pharmacol Ther. 2020;52:1253-1254.
PubMed

LAHARIE D, Riviere P
Editorial: biologics in the therapy of Crohn's disease-the fog clears.
Aliment Pharmacol Ther. 2020;52:1214-1215.
PubMed

MERTZ NORGARD B, Friedman S
Editorial: thiopurine/anti-TNF use during pregnancy-more encouraging safety data. Authors' reply.
Aliment Pharmacol Ther. 2020;52:1411.
PubMed

BETTENWORTH D, Bokemeyer A, Kou L, Lopez R, et al
Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn's disease strictures.
Aliment Pharmacol Ther. 2020;52:1104-1116.
PubMed Abstract available

TOWNSEND T, Razanskaite V, Dodd S, Storey D, et al
Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
Aliment Pharmacol Ther. 2020;52:1341-1352.
PubMed Abstract available

September 2020

BATTAT R, Vande Casteele N, Pai RK, Wang Z, et al
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.
Aliment Pharmacol Ther. 2020 Sep 27. doi: 10.1111/apt.16083.
PubMed Abstract available

JANGI S, Yoon H, Dulai PS, Valasek M, et al
Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.
Aliment Pharmacol Ther. 2020;52:1008-1016.
PubMed Abstract available

CHEE D, Goodhand JR, Ahmad T
Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?
Aliment Pharmacol Ther. 2020;52:1076-1077.
PubMed

APPLETON L, Day AS
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
Aliment Pharmacol Ther. 2020;52:1080-1081.
PubMed

ROBLIN X, Le Roy B, Paul S
Editorial: therapeutic drug monitoring for golimumab - ready for prime time?
Aliment Pharmacol Ther. 2020;52:1078-1079.
PubMed

BERTANI L, Fornai M, Antonioli L, Blandizzi C, et al
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' reply.
Aliment Pharmacol Ther. 2020;52:1082.
PubMed

KOPYLOV U
Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply.
Aliment Pharmacol Ther. 2020;52:907.
PubMed

DESAI D, Abraham P
Letter: monitoring interval for thiopurine therapy - a comment.
Aliment Pharmacol Ther. 2020;52:910.
PubMed

HUDSON J, Herfarth HH, Barnes EL
Letter: optimising response to ustekinumab therapy for patients with Crohn's disease.
Aliment Pharmacol Ther. 2020;52:906.
PubMed

JONES K, Baker K, Speight RA, Thompson NP, et al
Randomised clinical trial: combined impact and resistance training in adults with stable Crohn's disease.
Aliment Pharmacol Ther. 2020;52:964-975.
PubMed Abstract available

BROMS G, Kieler H, Ekbom A, Gissler M, et al
Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy.
Aliment Pharmacol Ther. 2020;52:843-854.
PubMed Abstract available

IBORRA M, Beltran B, Fernandez-Clotet A, Iglesias-Flores E, et al
Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
Aliment Pharmacol Ther. 2020;52:1017-1030.
PubMed Abstract available

August 2020

KHAN MU, Mushtaq K, Al-Ejji KMAA, Yakoob RA, et al
Letter: IBD nurse-a pivotal role in the time of the pandemic.
Aliment Pharmacol Ther. 2020;52:745.
PubMed

BERTANI L, Antonioli L, Blandizzi C
Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?
Aliment Pharmacol Ther. 2020;52:751-752.
PubMed

AL-ANI AH, Rentsch CA, Azim S, Bidgood E, et al
Letter: IBD nurse-pivotal role in the time of the pandemic. Authors' reply.
Aliment Pharmacol Ther. 2020;52:746-747.
PubMed

BIEMANS VBC, Hoentjen F, Pierik MJ
Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
Aliment Pharmacol Ther. 2020;52:753-754.
PubMed

MARSH A, Radford-Smith G
Editorial: obesity management and IBD-weight loss reduces IBD risk.
Aliment Pharmacol Ther. 2020;52:731-732.
PubMed

KANG B, Kim TJ, Choi J, Baek SY, et al
Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
Aliment Pharmacol Ther. 2020;52:459-470.
PubMed Abstract available

WALKER GJ, Lin S, Chanchlani N, Thomas A, et al
Quality improvement project identifies factors associated with delay in IBD diagnosis.
Aliment Pharmacol Ther. 2020;52:471-480.
PubMed Abstract available

BOHM M, Xu R, Zhang Y, Varma S, et al
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
Aliment Pharmacol Ther. 2020;52:669-681.
PubMed Abstract available

SEGAL JP, Smith PJ
Editorial: quality improvement project to identify factors associated with a delay in IBD diagnosis.
Aliment Pharmacol Ther. 2020;52:733-734.
PubMed

July 2020

BIEMANS VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, et al
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
Aliment Pharmacol Ther. 2020;52:123-134.
PubMed Abstract available

KABIR M, Fofaria R, Arebi N, Bassett P, et al
Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present).
Aliment Pharmacol Ther. 2020;52:5-19.
PubMed Abstract available

KOPYLOV U, Hanzel J, Liefferinckx C, De Marco D, et al
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
Aliment Pharmacol Ther. 2020;52:135-142.
PubMed Abstract available

KOCHAR B, Cai W, Cagan A, Ananthakrishnan AN, et al
Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases.
Aliment Pharmacol Ther. 2020;52:311-318.
PubMed Abstract available

THOMANN AK, Mak JWY, Zhang JW, Wuestenberg T, et al
Review article: bugs, inflammation and mood-a microbiota-based approach to psychiatric symptoms in inflammatory bowel diseases.
Aliment Pharmacol Ther. 2020;52:247-266.
PubMed Abstract available

DUMONT LM, Landman C, Sokol H, Beaugerie L, et al
Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
Aliment Pharmacol Ther. 2020;52:303-310.
PubMed Abstract available

BERTANI L, Fornai M, Fornili M, Antonioli L, et al
Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
Aliment Pharmacol Ther. 2020;52:284-291.
PubMed Abstract available

June 2020

YANG E, Panaccione N, Whitmire N, Dulai PS, et al
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
Aliment Pharmacol Ther. 2020;51:1031-1038.
PubMed Abstract available

LU C, Baraty B, Lee Robertson H, Filyk A, et al
Systematic review: medical therapy for fibrostenosing Crohn's disease.
Aliment Pharmacol Ther. 2020;51:1233-1246.
PubMed Abstract available

SRINIVASAN A, van Langenberg DR, Little RD, Sparrow MP, et al
A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
Aliment Pharmacol Ther. 2020;51:1342-1352.
PubMed Abstract available

PAPOUTSOPOULOU S, Satsangi J, Campbell BJ, Probert CS, et al
Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms.
Aliment Pharmacol Ther. 2020;51:1268-1285.
PubMed Abstract available

CZAJA AJ
Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
Aliment Pharmacol Ther. 2020;51:1286-1304.
PubMed Abstract available

May 2020

UNGARO RC, Aggarwal S, Topaloglu O, Lee WJ, et al
Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease.
Aliment Pharmacol Ther. 2020;51:831-842.
PubMed Abstract available

CHEUNG KS, Chen L, Chan EW, Seto WK, et al
Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer.
Aliment Pharmacol Ther. 2020;51:899-908.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.